

ANNUAL REPORT

2020-21

AMANTA HEALTHCARE LIMITED

Amanta Healthcare Limited.

AMANTA HEALTHCARE LIMITED

BOARD OF DIRECTORS

Shri Bhaveshbhai G. Patel
Shri Surendrabhai Shah
Dr. P.G. Shotriya
Shri Nimeshbhai R. Patel

Managing Director
Independent Director
Independent Director
Director

Company Secretary

Shivani Thaker

Auditors

M/s. Price Waterhouse Chartered Accountants LLP.
Ahmedabad.

Bankers

State Bank of India, Ahmedabad

Registered Office

5th Floor, Heritage,
Nr. Gujarat Vidhyapith,
Off. Ashram Road,
Ahmedabad – 380014.

Factory

Plot No.876,
N.H.No. 8, Hariyala,
Tal. Matar,
Dist. Kheda, Gujarat, India.

2020.2021

26th ANNUAL GENERAL MEETING

Day : Thursday
Date : 30-09-2021
Time : 11:00 a.m.
Venue : 10th Floor, Heritage,
Nr. Gujarat Vidhyapith,
Off. Ashram Road,
Ahmedabad – 380014.

Contents	Page No.
Notice of annual General Meeting	
Director's Report	
Auditor's Report	
Balance Sheet	
Profit and Loss Account	
Schedule to the Account	
Cash Flow Statement	
Balance Sheet Abstract & Company's Profile	
Proxy Form & Attendance Slip	

NOTICE

To,
The Shareholders
M/s. Amanta Healthcare Limited

Notice is hereby given that the **Twenty sixth Annual General Meeting** of M/s. Amanta Healthcare Limited will be held at 5th Floor, Heritage, Near Gujarat Vidhyapith, Off. Ashram Road, Ahmedabad - 380 014, on **30th September, 2021** at 1100 hours to transact the following business:

Ordinary Business:

- To receive and adopt Director's Report and Audited Balance Sheet & Profit and Loss Account for the year ended **31st March, 2021**.
- To appoint Shri Bhavesh Patel, who retire by rotation and being eligible offer himself for re-appointment.

Special Business:

1. To decide the remuneration of Y S THAKKAR & CO., the Cost Auditor of the Company for the Financial Year 2021-22.
2. Re- appointment of Managing Director of the Company .
3. To appoint Mr. Nimesh Patel who was appointed by the Board of Director of the Company as an Additional Director as on 14.12.2020 in the AGM.

PROPOSED RESOLUTIONS:

1. To decide the remuneration of CMA Y S THAKKAR & CO., the Cost Auditor of the Company for the Financial Year 2021-22.

"RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), M/s Y S THAKAR & Co., Cost Accountants, appointed as Cost Auditors by the Board of Directors of the Company to conduct the audit of the cost records of the Company for the Financial Year 2021-22, be paid a remuneration of Rs.50000/- and reimbursement of out of pocket expenses incurred by them in connection with the aforesaid audit."

"RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all acts and take all such steps as may be necessary to give effect to this resolution."

2. Re- appointment of Managing Director of the Company .



"RESOLVED THAT Mr. Bhavesh Patel be and is hereby re-appointed as the Managing Director of the Company for the term of 3 year for the period of 01.10.2021 to 30.09.2024 as per the provisions of section 196 of the Companies Act, 2013."

"FURTHER RESOLVED THAT the remuneration and terms & conditions for the appointment shall be as per the policy of the Company subject to the provisions of section 197 of the Companies Act, 2013 read with Schedule V to the Act and any further revisions shall be subject to the approval of the Board upon recommendation from the Managerial Committee from time to time."

"FURTHER RESOLVED THAT Mr. Shailesh Shah, President - Finance & Company Secretary of the Company be and is hereby authorized to comply with the necessary formalities of re-appointment of Managing Director and to give effect to the above resolutions."

3. Appointment of Shri Nimesh Patel

To appoint Mr. Nimesh Patel who was appointed by the Board of Director of the Company as an Additional Director as on 14.12.2020 and who holds office as such up to the date of this Annual General Meeting under Section 161 of the Companies Act, 2013 and in respect of whom the Company has, as required by Section 160 of the Companies Act, 2013 received notice in writing from some Members of the Company signifying their intention to propose him as a candidate for the office of Director of the Company.


"RESOLVED THAT Mr. Nimesh Patel appointed as Additional Director of the Company pursuant to section 161 of the Companies Act, 2013 and retires upon conclusion of this Annual General Meeting, the Company has received notice in writing from some members of the Company proposing his candidature for the office of Director. Mr. Nimesh Patel be and is hereby appointed as Director of the Company.

Notes:

1. A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY OR PROXIES TO ATTEND AND VOTE INSTEAD OF HIMSELF ON A POLL AND THAT A PROXY NEED NOT BE A MEMBER.
2. Corporate Members intending to send their authorized representatives to attend the Meeting are requested to send a certified true copy of the Board Resolution authorizing their representatives to attend and vote on their behalf at the Meeting.
3. Members are requested:
to kindly notify the change of address, if any, to the Company/their Depository Participant. to bring their attendance slip along with their copy of the Annual Report in the Meeting. to deposit the duly completed attendance slip at the Meeting.
4. Members desiring any information with regard to Accounts/Reports are requested to submit their queries addressed to the Company Secretary at least ten days in advance of the meeting so that the information called for can be made available at the meeting.

Place : Ahmedabad
Date : 31/08/2021

By the Order of the Board,
For, Amanta Healthcare Limited


S.M Shah
Chairman

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

In conformity with the provisions of Section 102 of the Companies Act, 2013, following Explanatory Statements sets out all material facts relating to the Special Businesses mentioned at Item No. 1 of the accompanying Notice dated 31.08.2021 and should be taken as forming part of the Notice.

ITEM NO.: 1

Your Directors would like to inform you that the Company has appointed M/s Y S THAKKAR & Co as the Cost Auditor of the Company pursuant to section 148(3) of the Companies Act, 2013 and Rule 6(2) of the Companies (Cost Records & Audit) Rules, 2014 for the financial year 2021-22 in the meeting of Board of Directors held on 24.06.2021

As per Rule 14 (a)(ii) of the Companies (Audit & Auditors) Rules, 2014, the remuneration of the Cost Auditor is required to be approved and ratified by the shareholders of the Company. The Board has approved an amount of Rs. 50,000/- on account of the Audit fees for the conduction of the Audit of Cost records of the Company for the financial year 2021-22.

Your Directors recommends ratification of the said Remuneration of the Cost Auditor by way of Special Resolution.

None of the Directors and/or the Key Managerial Personnel of the Company is concerned or interested in the proposed resolution.

ITEM NO: 2

Since the tenure of Mr. Bhavesh Patel as Managing Director ends on 30th September, 2021, he is required to be re-appointed as the Managing Director for 3 years 3 year for the period of 01.10.2021 to 30.09.2024 of the Company as per the provisions of section 196 of the Companies Act, 2013 and to consider the remuneration terms and conditions as per the provisions of section 197 read with Schedule V to the Companies Act, 2013. The remuneration structure as well as the detailed terms and conditions are as under:

1. Salary

Upto Rs. 10 lacs per month i.e. Rs. 120 lacs per annum.

The annual increment will be effective from time to time and will be decided by the Board upon recommendation of the Managerial Remuneration Committee within the limits prescribed under the provisions of Schedule V to the Companies Act, 2013.

2. Perquisites

CATEGORY - A:

(A) Housing:

House Rent Allowance or rent free unfurnished accomodation not exceeding 50% of the salary; Reimbursement of expenditure on gas, electricity, water, furnishing, etc. subject to a ceiling of 10% of salary.

(B) Medical Reimbursement:

Medical expenses incurred on self and / or family subject to ceiling of one month salary in a year or 3 months' salary over a period of 3 years.

(C) Leave Travel Concession:

Leave Travel Concession for self and family once in a year in accordance with any rules specified by the Company.

(D) Club Fees:

Membership fees in any two clubs not being admission and life membership fees.

(E) Personal Accident & Medical Insurance:

Personal Accident & Medical Insurance maximum upto Rs. 10 lacs p.a.

CATEGORY - B:

a) Contribution to provident fund, superannuation fund or annuity fund will not be included in the computation of ceiling on perquisites to the extent these either singly or put together are not taxable under Income Tax Act. Gratuity payable should not exceed half a month's salary for each completed year of service.

b) Encashment of leave at the end of the tenure will not be included in the computation in ceiling on perquisites.

CATEGORY - C:

Provision of car for use of the Company's business and telephone at residence will not be considered as perquisites. Personal long distance calls on telephone and use of car for private purpose shall be billed by the Company to the individual appointee concerned.

3. Commission

In addition to the Salary and Perquisites, Commission is also payable every year @ 1% of the net profits subject to section 197 of the Companies Act, 2013.


4. Minimum Remuneration

Notwithstanding anything contained herein, where in any financial year during the currency of Mr. Bhavesh Patel, the Company has no profits or its profits are inadequate, the Company will pay remuneration by way of salary and perquisites not exceeding the limits perscribed in Section II of Part II of Schedule V to the Companies Act, 2013.

None of the Directors, except Mr. Bhavesh Girishbhai Patel and Key Managerial Personnel of the Company or their relatives are in any way concerned or interested, financially or otherwise, in the said resolution.

Item No. 3

Mr.Nimesh Patel was appointed as an Additional Director w.e.f. December 14,2020 in accordance with the provisions of Section 161 of the Companies Act, 2013. Pursuant to Section 161 of the Companies Act, 2013 the above director holds office up to the date of the ensuing Annual General Meeting. In this regard the Company has received request in writing from a member of the company proposing Mr. Nimesh Patel candidature for appointment as Director of the Company in accordance with the provisions of Section 160 and all other applicable provisions of the Companies Act, 2013. None of the Directors, except Mr.Nimesh Patel and Key Managerial Personnel of the Company or their relatives are in any way concerned or interested, financially or otherwise, in the said resolution.



DIRECTOR'S REPORT

To,
The Shareholders,
Amanta Healthcare Limited
(Formerly known as Marck Biosciences Limited)

Your Directors have pleasure in submitting their **Twenty Sixth** of the Company together with the Audited Statements of Accounts for the year ended 31st March, 2021.

1. FINANCIAL RESULTS

The Company's financial performance for the year under review alongwith previous year's figures are given hereunder:

(Amt. Rs/ Lakh)

Particulars	Current Year	Previous Year
Net Sales /Income from Business Operations	17129.46	18436.79
Other Income	106.32	213.27
Total Income	17235.78	18650.06
Operating Profit	3939.98	3950.27
Interest	4013.18	3812.87
Profit before depreciation	-73.20	137.4
Depreciation	1702.37	1649.29
Profit after depreciation and Interest	-1775.57	-1511.89
Exceptional Items/Prior Items	0	0
Profit before Tax	-1775.57	-1511.89
Current Income Tax	369.26	377.33
Deferred Tax	38.55	-1.73
Net Profit after Tax	-2183.38	-1887.49
Balance carried to Balance Sheet	-2183.38	-1887.49
Earning per share (Basic)	-8.14	-7.04
Earning per Share(Diluted)	-8.14	-7.04

2. REVIEW OF BUSINESS OPERATIONS AND FUTURE PROSPECTS

Your directors are pleased to present the annual review of the year 2020-21. The year for the company has remained satisfactory.

- As you are aware, the current year is marred with Pandemic Corona. Your company's operations were affected initially in the month of April to June. However since July 20, the manufacturing operations has

remained stable.

- At marketing front, ours being Hospital Supply Product and not being part of Corona treatment therapy, the off take was marginally affected, since many planned/elective surgeries were deferred.
- In Export front, the demand was stable. Company executed single biggest order so far from Govt. tender of Ethiopia..

Overall Performance

- The total revenue for the current year is Rs17235.78 Lacs . as against Rs 18650.06 lacs of last year.
- The Revenue from Exports and Product Partnering verticals are Rs 82.13lacs as against Rs. 66.85lacs of previous year..

Manufacturing Operations

The manufacturing operations are satisfactory at Kheda. The capacity utilization is above 90% and there is no major break down during the year under review.

New initiatives

1. Debottlenecking of SteriPort line : The equipment is imported from China in the month of June/July 20. The custom clearance took some time. After lot of representations the equipment was cleared in the month of September 20.
2. The LVP Line 1 was disposed of in the month of July 20, and its place, filling line for SteriPort bottle was ordered from GF, Italy. The line has come in the month of April 21. The same is under installation.
3. To complete the range of product a Bottle forming equipment from M/s ASB Ltd. (a company having collaboration from ASB Japan), for fill volume of 250 ml and 1000 ml is ordered. Significant amount of Civil work will be involved for the same.

Post all the three initiative the total turnover is expected to reach Rs. 250 cr. plus on fully operational basis and the EBIDTA in the range of Rs. 70 cr. plus.

3. ANNUAL RETURN

The extracts of Annual Return pursuant to the provisions of Section 92 read with Rule 12 of the Companies (Management and administration) Rules, 2014 is furnished in **Annexure "A"** and forms part of this report.

4. NUMBER OF MEETINGS CONDUCTED DURING THE YEAR UNDER REVIEW

Meetings held during the financial year under review are as under:

Board Meeting,	
Sr. No.	Date of Board Meeting
1	19.06.2020
2	05.09.2020
3	14.12.2020
4	23.03.2021

Sr. No.	Date of Meeting Of Audit Committee
1	19.06.2020
2	07.09.2020
3	02.01.2021
4	31.03.2021
Sr. No.	Date of Meeting of CSR Committee
1	19.06.2020
2	21.03.2021
Sr No.	Date of Independent Directors Meeting
1	21.03.2021

5. DIRECTORS RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 134(5) of the Companies Act, 2013 the Board hereby submits its Responsibility Statement:

- In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period.
- The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- The Directors had prepared the annual accounts on a going concern basis; and
- The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

There is a Change in Board Composition During the Year.

During the year 2020-21 Shri Rohit Patel is no more with us and there was a casual vacancy which was filled by Shri Nimesh Patel w.e.f 14.12.2020.

Constitution of Board

Sr No.	Name of the Director	DIN	Date of resignation
1	Bhavesh Patel	00085505	-----
2	Nimesh Patel	09044772	-----
3	Shri Surendra M Shah	00016578	-----
4	Shri Pradyuman G Shrotriya	00822579	-----

6. MANAGERIAL REMUNERATION

Sr. No.	Name of the Director & Designation	Remuneration	Commission received from Holding/subsidiary [per month]
1	Mr. Bhavesh G. Patel	Rs 6,26,500 /-	Not Applicable

7. NETWORTH OF THE COMPANY

The Net Worth of the Company as on 31st March, 2021 766.95 is as compared to Rs. 2909.88 as on 31st March, 2020.

8. DECLARATION OF INDEPENDENT DIRECTORS

The Independent Directors have submitted their disclosures to the Board that they fulfill all the requirements as stipulated in Section 149(6) of the Companies Act, 2013 so as to qualify themselves to be appointed as Independent Directors under the provisions of the Companies Act, 2013 and the relevant rules.

9. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013

The Company has not granted any Loans, Guarantees or made investment under section 186 of the Companies Act, 2013 during the year under review.

10. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES

During the period under review, there are no contracts or arrangements made with the related party.

11. DIVIDEND

Due to inadequate profit, the company is not able to pay any dividend in the case of losses.

12. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND

The provisions of Section 125(2) of the Companies Act, 2013 do not apply as there was no dividend declared / paid in last year.

13. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

There was no material change from 31/03/21 till the date of report.

14. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The information pertaining to conservation of energy, technology absorption, Foreign exchange Earnings and outgo as required under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is furnished in Annexure "B" and forms part of this report.

15. STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK

MANAGEMENT POLICY OF THE COMPANY

The Company does have Risk Management Policy and the Company abides to the same. There were no accidents or mishaps during the year 2020-21

16. DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY INITIATIVES

The management of the Company has decided to enhance the scope of CSR activities by investing it into Education sector, Health sector and Art appreciation.

The Committee decided after consultation with the management views, to enhance the scope of the CSR activity in the area of Educational activities, Healthcare activities and maintenance of Environment and other safety measures in the nearby Villages/areas around the Factory Premise of the Company located at Kheda.

The Committee decided after consultation with the management views, to donate to those entities which primarily works for upliftment of education activities and healthcare activities of children and needy people.

Also the Committee has decided to enhance the scope in the area pertaining to Children activities in the nearby villages of Factory premise of the Company.

Management has to spent around Rs. 78.57 lakhs out of in place of Rs. 89.45 Lacs to be spent fot total of last four years from 2015-16 onwards due to insufficient profit ,CSR requirements are not cast on company from the year 2020-21 onwards.

As company lost Shri Rohit Patel during the year, Shri Nimeshbhai Patel became a member w.e.f 14.12.2021,therefore CSR Committee was reconstituted with new members as follows.

1. Shri S.M Shah- Independent Director
2. Shri P G Shrotriya- Independent Director
3. Shri Nimesh Patell-Director

The dtails of amount spend is as under

1	2	3	4	5	6	7
Sr.No	CSR project or activity identified	Sector in which the project is covered	Project or programs Location	Amount spent on the project or programs	Cumulative expenditure up to the reporting Period	Amount spent Direct or through implementi ngagency
1	Donation to Jayendra Patel Foundation	This Foundation works for the Health benefits of children, women and others.	All over Gujarat	Rs.38.17 Lacs	Rs.38.17 Lacs	Rs.38.17 Lacs

2	Donation to Jagatbhai Trust	Promotion for education activities to underprivileged children	All over Gujarat	Rs.40.00 Lacs	Rs.40.00 Lacs	Rs.40.00 Lacs
3	Donation to GUJARAT DARDI LOKKALYAN TRUST	Healthcare Services	Ahmedabad, Gujarat	Rs.25000	Rs.25000	Rs.25000
4	Grocery distribution to villages near kheda	Grocery distribution to villages near kheda	Kheda	Rs.15000	Rs.15000	Rs.15000
TOTAL					Rs.78.57 Lacs	

17. COMPANY'S POLICY RELATING TO DIRECTORS APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES

The Company has implemented a Policy relating to appointment of Directors, payment of Managerial remuneration, Directors' qualifications, positive attributes, independence of Directors and other related matters as provided under Section 178(3) of the Companies Act, 2013 and company abide to the same.

18. DISCLOSURE OF COMPOSITION OF AUDIT COMMITTEE AND PROVIDING VIGIL MECHANISM

The Audit Committee comprises of independent Directors namely, Mr. Surendra Shah, Mr. Pradyuman Shrotriya and Mr Nimesh Patel. All the recommendations made by the Audit Committee were accepted by the Board.

The Audit committee Has been reconstituted on 14th Dec,2020 due to demise of Shri Rohit Patel

The Company has established a vigil mechanism for the genuine concerns expressed by the employees and the committee overseas through other Directors. The Company has also provided adequate safeguards against victimization of employees and Directors who express their concerns. The Company has also provided direct access to the chairman of the Audit Committee on reporting issues concerning the interests of co-employees and the Company.

19. NOMINATION AND REMUNERATION COMMITTEE

The Company has also set up a Remuneration Committee of Directors consisting of Mr. Surendra Shah, Mr.Rohit Patel and Mr. Nimesh Patel

The Nomination and remuneration committee has been reconstituted on 14th December,2020 due to demise of Shri Rohit Patel with Mr. S.M Shah, Mr .Nimesh Patel and Dr. P.G Shrotriya.

The Committee identifies and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director, KMP or at Senior Management level and recommend to the Board his / her appointment. The Committee has discretion to decide whether qualification, expertise and experience possessed by a person are sufficient / satisfactory for the concerned position.

The Committee fixes remuneration of the Directors on the basis of their performance and also practice in the industry. The terms of reference of the Nomination & Remuneration Committee include review and recommendation to the Board of Directors of the remuneration paid to the Directors. The Committee meets as and when required to consider the remuneration of Directors. There was no requirement for any meeting.

20. CREDIT RATING

Facilities	Ratings Agency	Rating	Dated
Long-term Bank Facilities	CARE Rating	BB	September 04,2020
Short-term Bank Facilities	CARE Rating	A4	September 04,2020
Fixed Deposits	CARE Rating	BB(FD)	September 04,2020

21. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

The Company does not have any Subsidiary, Joint venture or Associate Company.

22. DEPOSITS

The details of deposits accepted/renewed during the year under review are furnished hereunder.

Sr. No.	Particulars	Amount in Rs
1	Amount accepted during the year	28344645
2	Amount remained unpaid or unclaimed as at the end of the year	
3.	whether there has been any default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases and the total amount involved	-NIL-
	(i) at the beginning of the year;	
	(ii) maximum during the year;	
	(iii) at the end of the year;	

23. DIRECTORS RETIRING BY ROTATION

In accordance with the provisions of the Articles of Association of the Company Shri Bhavesh Patel retires by rotation & being eligible, to offer him for re-appointment.

24. INSURANCE

The Company's properties including building, plant and machinery, stocks, stores, etc. continue to be adequately insured against risks such as fire, riot, strike, civil commotion, malicious damages, earthquake, flood, etc.

25. AUDITORS

Statutory Auditors

M/s Price Waterhouse Chartered Accountants LLP, Chartered Accountant Ahmedabad, the Statutory Auditors were - appointed as Statutory Auditors for a period of 5 Years in the Annual General Meeting held on 30th September, 2017 till the conclusion of 27th Annual general meeting. would be in accordance with the provisions of Section 141 of the Companies Act, 2013.

Secretarial Auditor

The Board has appointed M/s. Kashyap R. Mehta & Associates, Company Secretaries, Ahmedabad to conduct Secretarial Audit for the financial year 2020-21 in their Board Meeting held on 19th June, 2020. The Secretarial Audit Report for the financial year ended March 31, 2021 is annexed herewith marked as **Annexure "C"** to this Report.

Cost Auditor

Mr. Manish B. Analkat, Cost Accountant, Ahmedabad were appointed as Cost Auditors for the year 2020-21 in the Board Meeting held on 19th June, 2020. Their appointment and payment of remuneration are to be confirmed and approved in the ensuing Annual General Meeting.

26. 26. EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE STATUTORY AUDITORS AND THE PRACTICING COMPANY SECRETARY IN THEIR REPORTS

Statutory Auditor

The Statutory Auditor of the Company, M/s Price Waterhouse, Chartered Accountants have the below observations in their report and its reply is as under:

1. *There has been a slight delay in payment of statutory dues in a few cases.*

Reply From Board: Due to administrative constraints of reduced staff, there were slight delay.

Secretarial Auditor.

1. *There has been a slight delay in payment of statutory dues in a few cases.*

Reply From Board: Due to administrative constraints of reduced staff, there were slight delay.

2. *The Company has not been able to create necessary Debenture Redemption Reserve as required under Section 71 of the Act and rules made there under owing to losses in the year under review.*

Company has incurred loss during the year 2020-21, owing to that company could not be able to create necessary debenture redemption reserve.

3. *There are some defects /incompleteness in certain registered e-forms filed by the company with ROC.*

Company will take care of this in the future.

27. SHARES

Re- Classification of Authorised Share Capital /Conversion of OCPS and CCPS:

Authorised Sharecapital of the Amanta Healthcare Limited Rs.901500000 comprised of 90150000 equity shares of Rs.10 each.

BUY BACK OF SECURITIES

The Company has not bought back any of its securities during the year under review.

SWEAT EQUITY



28. DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013.

The Company has in place an Anti Sexual Harassment Policy, in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. During the year under review, the Company did not receive any complaints.

29. ACKNOWLEDGEMENTS

Your Directors would like to express their sincere appreciation for the assistance and cooperation received from the financial institution, banks, Government authorities, customer, vendors and members during the year under review. Your Director also wish to place on record their deep sense of appreciation for the committed services by the Company's executives, staff, and workers.

Last but not the least, your Directors wish to place on record their gratitude to the shareholders for their continued faith and trust placed in us and their interest in the progress of the Company.

**BY THE ORDER OF THE BOARD
For, AMANTA HEALTHCARE LTD**

Date: 31/08/2021

Place: Ahmedabad, Gujarat



S. M Shah



Bhavesh G. Patel

ANNEXURE – A**FORM NO. MGT-9
EXTRACT OF ANNUAL RETURN**

As on financial year ended on 31.03.2021x

Pursuant to Section 92 (3) of the Companies Act, 2013
and
Rule 12(1) of the Company (Management & Administration) Rules, 2014

I. REGISTRATION & OTHER DETAILS:

CIN	U24139GJ1994PLC023944
Registration Date	21.12.1994
Name of the Company	AMANTA HEALTHCARE LIMITED
Category/Sub-category of the Company	Public Company / Limited by Shares
Address of the Registered office & contact details	5 th Floor, Heritage, Near Gujarat Vidhyapith, Off. Ashram Road, Ahmedabad - 380 014 Gujarat. INDIA
Whether listed company	No
Name, Address & contact details of the Registrar & Transfer Agent, if any.	Link Intime (India) Private Limited
	Unit No. 303, 3rd Floor Shoppers Plaza V, Opp. Municipal Market, B/h. Shoppers Plaza II, Off. C. G. Road, Ahmedabad – 380 009

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

(All the business activities contributing 10 % or more of the total turnover of the company)

ame and Description of main products / services	NIC Code of the product / service	% to total turnover of the company
Normal Saline Injection 500ml	21002	13.05%
Normal Saline Injection 100ml	21002	15.66%
Ringer Lactate Injection 500ml	21002	9.5%
Dextrose & Normal Saline Injection 500ml	21002	7.91%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

(All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

Not Applicable

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

A) Category- wise Share Holding

Category of Shareholders	No. of Shares held at the end of the year[As on 31-March-2020]				No. of Shares held at the end of the year[As on 31-March-2021]				% Change
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoter's Shareholding									
(1) Indian									
a) Individual/HUF	4468591		4468591	16.66%	4583383		4583383	17.083	0.4%
b) Central Govt.	-	-	0	0.00%	-		-		0.0%
c) State Govt(s)	-	-	0	0.00%	-		-		0.0%
d) Bodies Corp.	3100000	-	3100000	11.64%	3100000		3100000	11.55%	0.1%
e) Banks / FI	-	-	0	0.00%	-		-		0.0%
f) Any other	-	-	0	0.00%	-		-		0.0%
Sub Total (A)(1)	7568591	146942	7715533	28.30%	7683383	0	7683383	28.64%	0.5%
(2) Foreign									
a) NRI-Individuals	6070936	1073744	1680838	62.92%	1680838		1680838	62.65%	0.3%
		4	0		0		0		
b) Other Individuals	-	-	0	0.00%	-		-		0.0%
c) Bodies Corp.	-	300,190	300190	1.13%	-	300,190	300190	1.12%	0.0%

d) Banks/FI	-	-	0	0.00%	-		-		0.0%
e) Any other	-	-	0	0.00%	-		-		0.0%
Sub Total (A) (1)	6070936	11037634	17108570	64.05%	16808380	300190	17108570	63.77%	-0.3%
Total Promoter's Shareholding (A)=(A) (1)+(A)(2)	13639527	11184576	24824103	92.35%	24491763	300190	24791953	92.41%	0.2%

B. Public Shareholding

	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	% Change
1. Institutions									
a) Mutual Funds	-	-	0	0.00%	-	-	0	0.00%	0.0%
b) Banks / FI	-	-	0	0.00%	-	-	0	0.00%	0.0%
c) Central Govt	-	-	0	0.00%	-	-	0	0.00%	0.0%
d) State Govt(s)	-	-	0	0.00%	-	-	0	0.00%	0.0%
e) Venture Capital Funds	-	-	0	0.00%	-	-	0	0.00%	0.0%
f) Insurance Companies	-	-	0	0.00%	-	-	0	0.00%	0.0%
g) FIIs	-	-	0	0.00%	-	-	0	0.00%	0.0%
h) Foreign Venture Capital Funds	-	-	0	0.00%	-	-	0	0.00%	0.0%
i) Others (specify)	-	-	0	0.00%	-	-	0	0.00%	0.0%
Sub-total (B)(1)	0	0	0	0.00%	0	0	0	0.00%	0.0%

2. Non-Institutions			0	0.00%			0	0.00%	0.0%
a) Bodies Corp.			0	0.00%			0	0.00%	0.0%
i) Indian	-	-	0	0.00%	-	-	0	0.00%	0.0%
ii) Overseas	-	-	0	0.00%	-	-	0	0.00%	0.0%
b) Individuals			0	0.00%			0	0.00%	0.0%
i) Individual shareholders holding nominal share capital upto Rs. 1 lacs	117400	845298	962698	3.59%	139046	845298	984344	3.67%	-0.1%
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lacs		246000	246000	0.92%		246000	246000	0.92%	0.0%
c) Others (HUF)	-	-	0	0.00%	10504	-	10504	0.04%	0.0%
Non Resident Indians			0	0.00%			0	0.00%	0.0%
i) Individual shareholders holding nominal share capital upto Rs. 1 lacs		14550	14550	0.05%		14550	14550	0.05%	0.0%

(ii) Individual shareholders holding nominal share capital in excess of Rs 1 lacs		782000	782000	2.91%	98400	683600	782000	2.91%	0.0%
			0	0.00%			0	0.00%	0.0%
Overseas Corporate Bodies	-	-	0	0.00%	-	-	0	0.00%	0.0%
Foreign Nationals	-	-	0	0.00%	-	-	0	0.00%	0.0%
Clearing Members	-	-	0	0.00%	-	-	0	0.00%	0.0%
Trusts	-	-	0	0.00%	-	-	0	0.00%	0.0%
Foreign Bodies - D R	-	-	0	0.00%	-	-	0	0.00%	0.0%
Sub-total (B)(2):-	117400	1887848	2005248	7.47%	247950	1789448	2037398	7.59%	-0.1%
Total Public Shareholding (B)=(B)(1) + (B)(2)	117400	1887848	2005248	7.47%	247950	1789448	2037398	7.59%	-0.1%
C. Shares held by Custodian for GDRs & ADRs	-	-	-						0.0%
Grand Total (A+B+C)	13756927	13072424	26829351	100.00%	24739713	2089638	26829351	100.00%	0.0%

B) Shareholding of Promoter

Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares held	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares held	
Rohitbhai.J.Patel	1,153,208	4.30%	4.06%	1,153,208	4.30%	4.06%	0.00%
Bhaveshbhai.G.Patel	3430173	12.9050%	12.47%	3430173	12.90%	12.47%	-0.0001%
Prafulbhai.J.Patel	4,471,936	16.67%	16.59%	4,471,936	16.67%	16.59%	0.00%
Jitendrabhai.J.Patel	3,376,338	12.58%	12.57%	3,376,338	12.58%	12.57%	0.00%
Milcent Appliances Pvt. Ltd.	3,100,000	11.55%	11.55%	3,100,000	11.55%	11.55%	0.00%
MNJ Jackson Inc.	300,190	1.12%	1.12%	300,190	1.12%	1.12%	0.00%
Vishal Patel	3,284,288	12.24%	12.24%	3,284,288	12.24%	12.24%	0.00%
Kiritbhai.A. Desai	1,133,079	4.22%	4.22%	1,133,079	4.22%	4.22%	0.00%
Pravinbhai.D.Mehta	2,804,763	10.45%	10.43%	2,804,763	10.45%	10.43%	0.00%
Niranjanbhai Patel	1,725,951	6.43%	6.39%	1,725,951	6.43%	6.39%	0.00%
Sarla Desai	12024	0.04%	0.00%	12024	0.04%	0.00%	0.00%
Veenaben J. Patel	1	0.00%	0.00%	1	0.00%	0.00%	0.00%
Jayshreeben R. Patel	1	0.00%	0.00%	1	0.00%	0.00%	0.00%
Manisha Patel	1	0.00%	0.00%	1	0.00%	0.00%	0.00%
Total	24791953	92.41%	91.65%	24791953	92.41%	91.65%	0.00%

C) Change in Promoters' Shareholding (please specify, if there is no change)

Sr. No.	Name of the Shareholder	Shareholding at the beginning of the year (April 1, 2020)		Increase / Decrease in shareholding		Cumulative Shareholding at the end of the year (March 31, 2021)	
		No. of Shares	% of Shares	Increase	Decrease	No. of Shares	% of Shares
1	Rohitbhai.J.Patel	1,153,208	4.30%	0	0	1,153,208	4.30%
2	Bhaveshbhai.G.Patel	3,430,173	12.90%	0		3,430,173	12.90%
3	Prafulbhai.J.Patel	4,471,936	16.67%	0	0	4,471,936	16.67%
4	Jitendrabhai.J.Patel	3,376,338	12.58%	0	0	3,376,338	12.58%
5	Milcent Appliances Pvt. Ltd.	3,100,000	11.55%	0	0	3,100,000	11.55%
6	MNJ Jackson Inc.	300,190	1.12%	0	0	300,190	1.12%

7	Vishal Patel	3,284,288	12.24%	0	0	3,284,288	12.24%
8	Kiritbhai.A. Desai	1,133,079	4.22%	0	0	1,133,079	4.22%
9	Pravinbhai.D.Mehta	2804763	10.45%	0	0	2,804,763	10.45%
10	Niranjambhai Patel	1725951	6.43%	0	0	1,725,951	6.43%
11	Sarla Desai	12,024	0.04%	0	0	12,024	0.04%
12	Veenaben Patel	1	0.00%	0	0	1	0.00%
13	Jayshreeben R patel	1	0.00%	0	0	1	0.00%
14	Manishaben Patel	1	0.00%	0	0	1	0.00%
Total		24791953	92.41%	0	0	24791953	92.41%

**D) Shareholding Pattern of top ten Shareholders:
(Other than Directors, Promoters and Holders of GDRs and ADRs):**

Sr. No.	Name of the Shareholder	Shareholding at the beginning of the year (April 1, 2020)		Increase / Decrease in shareholding		Cumulative Shareholding at the end of the year (March 31, 2021)	
		No.of Shares	% of Shares	Increase	Decrease	No.of Shares	% of Shares
1	Jagdish Patel	256,500	0.96%	0	0	256,500	0.96%
2	Sharmishta Patel	105,400	0.39%	0	0	105,400	0.39%
3	Chandrakant Premchand Shah	98,400	0.37%	0	0	98,400	0.37%
4	Rajeshree Tarun Shah	71,500	0.27%	0	0	71,500	0.27%
5	Mihir Bipinchandra	79,672	0.30%	0	0	79,672	0.30%
6	Manojkumar Sedani	61,950	0.23%	0	0	61,950	0.23%
7	Pravinchandra.K.Lakhani	61,950	0.23%	0	0	61,950	0.23%
8	Induben.C.Patel	54,000	0.20%	0	0	54,000	0.20%
9	Ashwin.R.Patel	48,900	0.18%	0	0	48,900	0.18%
10	Jagrut.N.Patel	45,000	0.17%	0	0	45,000	0.17%
	Total	883,272	3.29%	0	0	883,272	3.29%

V.
INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

(Amount in Rs. Lakhs)

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	23015.51	735.18	1102.39	24853.08
ii) Interest due but not paid				
iii) Interest accrued but not due	3377.51		0	3377.51
Total (i+ii+iii)	26393.02	735.18	1102.39	28230.59
Change in Indebtedness during the financial year				
* Addition	3182.36		22.04	3204.4
* Reduction	2397.28	25.09	638.62	3060.99
Net Change				
Indebtedness at the end of the financial year				
i) Principal Amount	21921.05	710.09	485.81	23116.95
ii) Interest due but not paid				
iii) Interest accrued but not due	5257.05		0.00	5257.05
Total (i+ii+iii)	27178.10	710.09	485.81	28374.00

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL	
A. Remuneration to Managing Director, Whole-time Directors and/or Manager:	
Particulars of Remuneration:	Total
Mr. Bhavesh G. Patel	Amount (Rs.)
Gross salary	6681540

(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	39,600
(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-
Stock Option	-
Sweat Equity	-
Commission	
- as % of profit	-
- others, specify...	-
Others, Gulmohar Greens	-
Total (A)	6721140
Ceiling as per the Act	12,000,000

Independent Directors	Mr. Surendra Shah	Dr. P. G. Shrotriya	Total
Fee for attending Board & Committee meetings	50000	40000	90000
Commission	-	-	-
Others, please specify	-	-	-
Total (2)	50000	40000	90000
Grand Total (1) & (2)	50000	40000	90000

Particulars of Remuneration	Key Managerial Personnel			
	MD	CS	CFO	Total
Gross salary				
(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	6681540	306960	4140808	10228116
(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	39,600	-	39,600	79,200.00

(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-	
Stock Option	-	-	-	
Sweat Equity	-	-	-	
Commission	-	-	-	
- as % of profit	-	-	-	
others, specify...	-	-	-	
Others (Gulmohar Greens)	-	-	-	-
Total	6721140	306960	4180408	10307316

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority RD / NCLT/ COURT]	Appeal made if any (give Details)
A. COMPANY					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
B. DIRECTORS					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
C. OTHER OFFICERS IN DEFAULT					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-

ANNEXURE - B

PARTICULARS WITH RESPECT TO DISCLOSURE IN TERMS OF COMPANIES (ACCOUNTS) RULES, 2014

A. CONSERVATION OF ENERGY:

1. Energy conservation measures taken:

The company is constantly taking measures for conservation of energy. With minor modification in equipment company is now using residual unusable woods from saw dust in the boiler. This has resulted in saving in saw dust consumption. Company is also maintaining power factor at 0.99 with installation of equipments like variable drive, UPS etc. Company also carries out regular maintenance of the equipment and 'Energy Audit'.

2. Additional investments and proposals, if any, being implemented for reduction of consumption of energy:

No major fresh investment is envisaged.

3. Impact of the measures at (a) and (b) above for reduction for energy consumption and consequent impact on the cost of production of goods :

It will conserve power and reduce production loss/plastic consumption.

4. Total energy consumption and energy consumption per unit of production as per Form A of the Annexure in respect of industries specified in the Schedule thereto

As per FORM A

B. TECHNOLOGY ABSORPTION :

Since inception the Company has adopted Form, Fill and Seal (FFS) technology, being low cost manufacturing technology. The Company has been continuously adapting changes in technology for better productivity and quality of its products.

All the machineries are imported and technology is fully absorbed.

C. FOREIGN EXCHANGE EARNING AND OUTFLOW:-			
Total Foreign Exchange Used and Earned (in Rs. Lacs) :			
1.	Foreign Exchange Earned		5927.58
2.	Foreign Exchange Used		191.71
2.1	Commision Expense		141.34
2.2	Foreign Travelling		
2.3	Other		50.37

					KHEDA		GOA		
	2020-21	2019-20	2018-19	2017-18	Current Year	Previous Year		Current Year	Previous Year
1. Electricity									
(a) Purchased:									
1. Units	12,287,953	14,099,678	12,872,713	12,891,011	12,548,400	11,386,540		168,561	1,681,570
2. Total Amount (Rs. in lacs)	972.20	1,128.66	988.56	963.03	924.31	893.42		8.93	89.55
3. Rate per Unit (Rs.)	7.91	8	7.68	7.47	7.37	7.84		5.3	5.32
(b) Own Generation Through D.G. Sets:									
4. Units					20,004	94,183	-		69,726
5. Litre of Diesel Oil	12,542	22,732	17,773	36,387	20,000	28,766	-		23,400
6. Total Amt. (Rs. In Lacs)	9.16	15.58	9.03	18.47	9.88	20.3	-		11.9
7. Cost/Unit Rs.	73.06	68.53	50.81	50.76	49.39	21.55	-		17.07
2. Furnace Oil:									
8. Quantity in litre					-	-	-	-	-
9. Total Amt. (Rs. in Lacs)					-	-	-	-	-
10. Average rate (Rs. / Ltr.)					-	-	-	-	-
3. Saw Dust:									
11. Purchase (In Kg)	14,635,760	17,197,081	15,847,724	15,451,251	16,490,398	12,240,559	-		3,026,385
12. Total Amount (Rs. In Lacs)	489.28	689.58	577.58	530.07	522.09	409.52	-		129.27

B – 403, 'The First', Beside ITC Narmada Hotel, Behind Keshavbaug, Vastrapur, Ahmedabad – 380 015

Tel. No. : 079-2970 2975 / 76 / 77 • Mobile: 98250 15581 • Email : kashyaprmehta@hotmail.com • Web : www.cskashyap.in

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to following observations:

- 1. There have been minor delays in payment of certain statutory dues.*
- 2. The Company has not been able to create necessary Debenture Redemption Reserve as required under Section 71 of the Act and rules made there under owing to losses in the year under review.*
- 3. There are some defects / incompleteness in certain registered e-forms filed by the Company with ROC.*

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period the Company has not passed any Special Resolution.



Place: Ahmedabad
Date: 28th August, 2021

FOR KASHYAP R. MEHTA & ASSOCIATES
COMPANY SECRETARIES
FRN: S2011GJ166500

KASHYAP R. MEHTA
PROPRIETOR
FCS-1821 : COP-2052 : PR-583/2019
UDIN: F001821C000849085

Note: This report is to be read with our letter of even date which is annexed as **Annexure-1** and forms an integral part of this report.

Disclaimer: Due to restricted movement amid COVID-19 pandemic, we have conducted the assignment by examining the Secretarial Records including Minutes, Documents, Registers and other records etc., and some of them received by way of electronic mode from the Company and could not be verified from the original records. The management has confirmed that the records submitted to us are true and correct. This Report is limited to the Statutory Compliances on laws / regulations / guidelines listed in our report which have been complied by the Company pertaining to Financial Year 2019-20. We are not commenting on the Statutory Compliances whose due dates are extended by Regulators from time to time due to COVID-19 or still there is time line to comply with such compliances.

B – 403, 'The First', Beside ITC Narmada Hotel, Behind Keshavbaug, Vastrapur, Ahmedabad – 380 015

Tel. No. : 079-2970 2975 / 76 / 77 • Mobile: 98250 15581 • Email : kashyaprmehta@hotmail.com • Web : www.cskashyap.in**Annexure - 1**

To,
The Members
Amanta Healthcare Limited.

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.



Place: Ahmedabad
Date: 28th August, 2021

**FOR KASHYAP R. MEHTA & ASSOCIATES
COMPANY SECRETARIES
FRN: S2011GJ166500**

**KASHYAP R. MEHTA
PROPRIETOR
FCS-1821 : COP-2052 : PR-583/2019
UDIN: F001821C000849085**

Price Waterhouse Chartered Accountants LLP

Independent auditors' report

To the Members of Amanta Healthcare Limited

Report on the audit of the financial statements

Opinion


1. We have audited the accompanying financial statements of Amanta Healthcare Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2021, and the Statement of Profit and Loss, and Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, and its loss and its cash flows for the year then ended.

Basis for opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

4. We draw your attention to Note 43 to the financial statements, regarding management's assessment of the impact on the financial statements due to restrictions and other conditions related to the Covid-19 pandemic, for which a definitive assessment of the impact in the subsequent period is dependent upon circumstances as they evolve. Our opinion is not modified in respect of this matter.



Price Waterhouse Chartered Accountants LLP, 1701, 17th Floor, Shapath V, Opp. Karnavati Club, S G Highway
Ahmedabad - 380 051, Gujarat, India
T: +91 (79) 3091 7000, F: +91 (79) 3091 7082

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITORS' REPORT

To the Members of Amanta Healthcare Limited
Report on audit of the Financial Statements
Page 2 of 5

Other Information

5. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's report but does not include the financial statements and our auditor's report thereon.


Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the financial statements

6. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
7. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.




Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITORS' REPORT

To the Members of Amanta Healthcare Limited
Report on audit of the Financial Statements
Page 3 of 5

Auditor's responsibilities for the audit of the financial statements

8. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
9. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.




Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITORS' REPORT

To the Members of Amanta Healthcare Limited
Report on audit of the Financial Statements
Page 4 of 5

Report on other legal and regulatory requirements

11. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure B a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
12. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act.
 - (e) On the basis of the written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements – Refer Note 36 to the financial statements.
 - ii. The Company has long-term contracts as at March 31, 2021 for which there were no material foreseeable losses. The Company did not have any derivative contracts as at March 31, 2021.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended March 31, 2021.




Price Waterhouse Chartered Accountants LLP

INDEPENDENT AUDITORS' REPORT

To the Members of Amanta Healthcare Limited
Report on audit of the Financial Statements
Page 5 of 5

- iv. The reporting on disclosures relating to Specified Bank Notes is not applicable to the Company for the year ended March 31, 2021.
13. The Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016
Chartered Accountants



Viren Shah
Partner
Membership Number: 046521
UDIN: 21046521AAAAFU3440

Place: Ahmedabad
Date: August 31, 2021

Price Waterhouse Chartered Accountants LLP

Annexure A to Independent Auditors' Report

Referred to in paragraph 12(f) of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements for the year ended March 31, 2021

Page 1 of 2

Report on the Internal Financial Controls with reference to financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act


1. We have audited the internal financial controls with reference to financial statements of Amanta Healthcare Limited ("the Company") as of March 31, 2021 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

2. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing deemed to be prescribed under section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to financial statements.



Price Waterhouse Chartered Accountants LLP

Annexure A to Independent Auditors' Report

Referred to in paragraph 12(f) of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements for the year ended March 31, 2021

Page 2 of 2

Meaning of Internal Financial Controls with reference to financial statements

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.


Inherent Limitations of Internal Financial Controls with reference to financial statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. Also refer paragraph 4 of our main audit report.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016
Chartered Accountants



Viren Shah
Partner

Membership Number: 046521
UDIN: 21046521AAAAFU3440


Place: Ahmedabad
Date: August 31, 2021

Price Waterhouse Chartered Accountants LLP

Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements as of and for the year ended March 31, 2021

- i. (a) The Company is maintaining proper records showing full particulars, including quantitative details and situation, of fixed assets [Property, plant and equipment (tangible assets)].
(b) The fixed assets [Property, plant and equipment (tangible assets)] are physically verified by the Management according to a phased programme designed to cover all the items over a period of 3 years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, a portion of the fixed assets [Property, plant and equipment (tangible assets)] have been physically verified by the Management during the year and no material discrepancies have been noticed on such verification.
(c) The title deeds of immovable properties, as disclosed in Note 12 Property, plant and equipment (tangible assets) to the financial statements, are held in the name of the Company.
- ii. The physical verification of inventory excluding stocks with third parties have been conducted at reasonable intervals by the Management during the year. In respect of inventory lying with third parties, these have substantially been confirmed by them. The discrepancies noticed on physical verification of inventory as compared to book records were not material.
- iii. The Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189 of the Act. Therefore, the provisions of Clause 3(iii), (iii)(a), (iii)(b) and (iii)(c) of the said Order are not applicable to the Company.
- iv. The Company has not granted any loans or made any investments or provided any guarantees or security to the parties covered under Section 185 and 186 of the Act. Therefore, the provisions of Clause 3(iv) of the said Order are not applicable to the Company.
- v. In our opinion, and according to the information and explanations given to us, the Company has complied with the provisions of Sections 73, 74, 75 and 76 or any other relevant provisions of the Act and the Rules framed thereunder to the extent notified, with regard to the deposits accepted. According to the information and explanations given to us, no order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal on the Company in respect of the aforesaid deposits.
- vi. Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as specified under Section 148(1) of the Act in respect of its products. We have broadly reviewed the same, and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
- vii. (a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is generally regular in depositing undisputed statutory dues in respect of provident fund, professional tax, employees' state insurance and income tax, though there has been a slight delay in a few cases, and is regular in depositing undisputed statutory dues, including sales tax, service tax, duty of customs, duty of excise, value added tax, cess, goods and service tax and other material statutory dues, as



Price Waterhouse Chartered Accountants LLP

Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements for the year ended March 31, 2021


Page 2 of 3

applicable, with the appropriate authorities. Also refer note 41 to the financial statements regarding management's assessment on certain matters relating to provident fund.

- (b) According to the information and explanations given to us and the records of the Company examined by us, there are no dues of income tax, sales tax, duty of customs and duty of excise, which have not been deposited on account of any dispute. The particulars of dues of service tax as at March 31, 2021 which have not been deposited on account of a dispute, are as follows:

Name of the statute	Nature of dues	Amount (Rs. in lakhs)	Period to which the amount relates	Forum where the dispute is pending
Finance Act, 1994	Service Tax	5.44	2008-09	Custom, Excise and Service Tax Appellate Tribunal
Finance Act, 1994	Service Tax	2.02	2008-09	Commissioner (Appeals III)

- viii. According to the records of the Company examined by us and the information and explanation given to us, the Company has not defaulted in repayment of loans or borrowings to any financial institution or bank or dues to debenture holders as at the balance sheet date. The Company did not have any outstanding loans or borrowings to any Government as at the balance sheet date.
- ix. In our opinion, and according to the information and explanations given to us, the moneys raised by way of loans have been applied for the purposes for which they were obtained. The Company has not raised any moneys by way of initial public offer, further public offer (including debt instruments).
- x. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud by the Company or on the Company by its officers or employees, noticed or reported during the year, nor have we been informed of any such case by the Management.
- xi. The Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act. Also refer paragraph 13 of our main audit report.
- xii. As the Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it, the provisions of Clause 3(xii) of the Order are not applicable to the Company.
- xiii. The Company has entered into transactions with related parties in compliance with the provisions of Sections 177 and 188 of the Act. The details of such related party transactions have been disclosed in the financial statements as required under Accounting Standard (AS) 18 specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.



Price Waterhouse Chartered Accountants LLP


Annexure B to Independent Auditors' Report

Referred to in paragraph 11 of the Independent Auditors' Report of even date to the members of Amanta Healthcare Limited on the financial statements for the year ended March 31, 2021

Page 3 of 3

- xiv. The Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of Clause 3(xiv) of the Order are not applicable to the Company.
- xv. The Company has not entered into any non-cash transactions with its directors or persons connected with him. Accordingly, the provisions of Clause 3(xv) of the Order are not applicable to the Company.
- xvi. The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the provisions of Clause 3(xvi) of the Order are not applicable to the Company.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016
Chartered Accountants



Viren Shah
Partner

Membership Number: 046521
UDIN: 21046521AAAAFU3440

Place: Ahmedabad
Date: August 31, 2021

Amanta Healthcare Limited
Balance Sheet as at 31st March, 2021

Particulars	Note No.	Amount (Rs. in lakhs)	
		As at 31st March, 2021	As at 31st March, 2020
Equity And Liabilities			
Shareholders' Funds			
(a) Share capital	2	2,682.94	2,682.94
(b) Reserves and surplus	3	(1,956.47)	226.94
		<u>726.47</u>	<u>2,909.88</u>
Non-Current Liabilities			
(a) Long-term borrowings	4	15,808.49	19,244.01
(b) Deferred tax liabilities (net)	5	3,879.79	3,848.81
(c) Other long-term liabilities	6	6,050.85	5,026.78
(d) Long-term provisions	7	454.32	407.64
		<u>26,193.45</u>	<u>28,527.24</u>
Current Liabilities			
(a) Short-term borrowings	8	3,788.37	3,421.10
(b) Trade payables			
(i) Total outstanding dues of micro enterprises and small enterprises; and	9	466.46	138.76
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	9	2,063.48	1,588.03
(c) Other current liabilities	10	5,644.04	1,897.02
(d) Short-term provisions	11	328.76	339.27
		<u>12,291.11</u>	<u>7,384.18</u>
Total		<u><u>39,211.03</u></u>	<u><u>38,821.30</u></u>
Assets			
Non-Current Assets			
(a) Property, plant and equipment (Tangible assets)	12	24,074.01	24,198.45
(b) Intangible assets	12	107.03	191.96
(c) Non-current investments	13	-	10.00
(d) Long-term loans and advances	14	1,736.79	3,579.20
(e) Other non-current assets	15	215.33	300.66
		<u>26,133.16</u>	<u>28,280.27</u>
Current Assets			
(a) Current Investments	16	150.00	-
(b) Inventories	17	5,724.07	3,933.50
(c) Trade receivables	18	5,147.86	5,207.98
(d) Cash and bank balances	19	887.30	622.19
(e) Short-term loans and advances	20	845.36	423.01
(f) Other current assets	21	323.28	354.35
		<u>13,077.87</u>	<u>10,541.03</u>
Total		<u><u>39,211.03</u></u>	<u><u>38,821.30</u></u>

See accompanying notes to the financial statements

In terms of our report of even date.

For Price Waterhouse Chartered Accountants LLP
Chartered Accountants

Firm Registration No.: 012754N/N500016

Viren Shah

Viren Shah
Partner
Membership No: 046521

Place: Ahmedabad

Date: August 31, 2021



For and on behalf of the Board of Directors

S. M. Shah *Bhaves G. Patel*

Surendra M. Shah

Bhaves G. Patel

Director

Managing Director

DIN: 00016578

DIN: 00085505

Shailish M. Shah
Shailish M. Shah
Chief Finance Officer

Shwani Thaker
Shwani Thaker
Company Secretary

Place: Ahmedabad

Date: August 28, 2021

Amanta Healthcare Limited

Statement of Profit and Loss for the year ended 31st March, 2021

Particulars	Note No.	Amount (Rs. in lakhs)	
		Year ended 31st March, 2021	Year ended 31st March, 2020
INCOME			
Revenue from operations	22	17,129.46	18,436.79
Other income	23	106.32	213.27
Total Revenue		17,235.78	18,650.06
EXPENSES			
Cost of materials consumed	24	5,894.65	6,550.54
Purchases of stock-in-trade		489.69	221.95
Changes in inventories of finished goods, work-in-process and stock-in-trade	25	(1,431.89)	(389.93)
Employee benefits expense	26	3,443.00	3,329.40
Finance costs	27	4,013.18	3,812.87
Depreciation and amortisation expense	12	1,702.37	1,649.29
Other expenses	28	4,900.35	4,987.83
Total Expenses		19,011.35	20,161.95
Loss before tax		(1,775.57)	(1,511.89)
Tax Expense:			
Current Tax		332.40	327.10
Short provision of tax relating to earlier years		44.46	25.73
Deferred Tax		30.98	22.76
Total Tax Expenses		407.84	375.59
Loss for the year		(2,183.41)	(1,887.48)
Earnings per Equity Share [Nominal Value per share: Rs. 10 (March 31, 2020: Rs. 10)]	41		
Basic		(8.14)	(7.04)
Diluted		(8.14)	(7.04)
See accompanying notes to the financial statements			

See accompanying notes to the financial statements

In terms of our report of even date.

For Price Waterhouse Chartered Accountants LLP

Chartered Accountants

Firm Registration No.: 012754N/N500016

Viren Shah

Viren Shah

Partner

Membership No: 046521

Place: Ahmedabad

Date: *August 31, 2021*



For and on behalf of the Board of Directors

S. M. Shah
Surendra M. Shah

Director

DIN: 00016578

Shailish M. Shah

Shailish M. Shah

Chief Finance Officer

Place: Ahmedabad

Date: *August 28, 2021*

Bhavesh G. Patel
Bhavesh G. Patel

Managing Director

DIN: 00085505


Shivani Thaker

Shivani Thaker

Company Secretary

Amanta Healthcare Limited
Cash Flow Statement for the year ended 31st March, 2021

Particulars	Amount (Rs. in lakhs)	
	Year ended 31st March, 2021	Year ended 31st March, 2020
A. CASH FLOW FROM OPERATING ACTIVITIES		
Loss before tax	(1,775.57)	(1,511.89)
Adjustments for:		
Loss on sale of assets	15.34	9.03
Unrealised foreign exchange gain	(15.72)	(37.15)
Provision for doubtful trade receivables	75.99	29.24
Depreciation and amortisation expense	1,702.37	1,649.29
Finance costs	4,013.18	3,812.87
Interest income	(65.04)	(40.20)
Liabilities no longer required written back (net)	(6.73)	(8.06)
Operating Profit before Working Capital changes	4,216.24	3,903.13
Changes in Working Capital:		
Adjustments for (increase)/decrease in operating assets:		
Inventories	(1,790.57)	(96.05)
Trade receivables	(272.57)	22.67
Short-term loans and advances	(89.95)	279.65
Long-term loans and advances	(17.28)	43.50
Other current assets	8.35	29.61
Adjustments for increase/(decrease) in operating liabilities:		
Trade payables	809.88	(459.69)
Other current liabilities	(90.52)	19.33
Other long-term liabilities	-	(5.45)
Short-term provisions	1.58	(15.83)
Long-term provisions	46.68	82.93
Cash generated from operations	2,821.84	3,803.80
Income taxes paid	517.51	(16.09)
Net cash flow from operating activities	3,339.35	3,787.71
B. CASH FLOW FROM INVESTING ACTIVITIES		
Capital expenditure on property, plant and equipment including CWIP and capital advances	(1,348.55)	(1,076.30)
Sale of fixed assets	152.29	2.94
Current investments	(150.00)	-
Bank Deposits placed	(750.00)	(59.55)
Proceeds from withdrawal of Bank Deposits	425.36	5.78
Interest received	59.45	35.86
Sale of investment in mutual fund	11.40	-
Net cash used in investing activities	(1,600.05)	(1,091.27)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long-term borrowings	380.00	143.28
Repayment of Long-term borrowings	(399.37)	(1,108.77)
Net proceeds from Short-term borrowings	367.27	(770.64)
Finance Costs paid	(2,105.35)	(1,774.65)
Net cash used in financing activities	(1,757.45)	(3,510.78)
Net decrease in Cash and Cash Equivalents (A+B+C)	(18.15)	(814.34)
Opening balance of Cash and Cash Equivalents	106.45	920.79
Closing balance of Cash and Cash Equivalents	88.30	106.45



Amanta Healthcare Limited
Cash Flow Statement for the year ended 31st March, 2021

Amount (Rs. in lakhs)

Note: 1 Reconciliation of cash and cash equivalents with Balance Sheet:

	As at 31st March, 2021	As at 31st March, 2020
Closing balance of Cash and Cash Equivalents	88.30	106.45
Add: Bank balances not considered as cash and cash equivalents		
	799.00	515.74
Cash and Bank Balances as per Balance Sheet (Refer Note 19)	887.30	622.19

Note: 2 The cash flow statement has been prepared under the "indirect method" as set out in Accounting Standard - 3 "Cash Flow Statement".

Note: 3 Cash flows from operating activities includes Rs. 78.57 lakhs (Previous year Rs. 94.73 lakhs) being expenses towards Corporate Social Responsibility initiatives. (Refer note no. 39).

Note: 4 The previous year's figures have been regrouped wherever necessary to make them comparable with current year's figures.

See accompanying notes to the financial statements

In terms of our report of even date.

For Price Waterhouse Chartered Accountants LLP
Chartered Accountants
Firm Registration No.: 012754N/N500016





Viren Shah
Partner
Membership No: 046521

Place: Ahmedabad

Date: August 31, 2021


For and on behalf of the Board of Directors


Surendra M. Shah
Director
DIN: 00016378


Shailesh M. Shah
Chief Finance Officer

Place: Ahmedabad

Date: August 28, 2021



Bhavesh G. Patel
Managing Director
DIN: 00085505


Shvanti Thaker
Company Secretary



AMANTA HEALTHCARE LIMITED
Notes to Financial Statements

Corporate Information:

M/s Amanta Healthcare Limited ('the Company') is a Sterile liquid pharmaceutical products manufacturing and formulation development Company having head quarter at Ahmedabad, Gujarat, India. It has manufacturing facilities in the state of Gujarat. The Company manufactures Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs). The technology deployed for manufacturing is Blow Fill Seal (BFS), Injection Stretch Blow Molding (ISBM) and conventional three-Piece line. The product group comprises of Fluid Therapy, Formulations, Diluents, Ophthalmic, Respule and Irrigation Solutions, etc. The Company markets its products in India as well as in the international market. In India, it has pan India presence. In international market, it has distributors across 5 continents.

Note-1: - SIGNIFICANT ACCOUNTING POLICIES

1.1 Basis of Preparation:

These financial statements have been prepared in accordance with the generally accepted accounting principles in India under the historical cost convention on accrual basis and following the going concern assumption. These financial statements have been prepared to comply in all material aspects with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended), specified under section 133 and other relevant provisions of the Companies Act, 2013. Refer Note 43 and 44.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current – non-current classification of assets and liabilities.


1.2. Use of Estimates:

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognized in the periods in which the results are known / materialise.

1.3 Property, Plant and Equipment and Depreciation/Amortization:

A. Tangible Assets:

- i. Tangible Assets are stated at cost, net of accumulated depreciation. Cost comprises of the purchase price, non-refundable taxes and directly attributable expenses incurred to bring the asset to the location and condition necessary for it to be capable of being operated in the manner intended by management. Subsequent costs related to an item of Property, Plant and Equipment are recognised in the carrying amount of the item if the recognition criteria are met.
- ii. Depreciable amount for assets is the cost of an asset, or other amount substituted for cost, less its estimated residual value. Depreciation for the asset purchased/sold during the period is proportionately charged. Depreciation on tangible fixed assets has been provided on the straight-line method as per the useful life prescribed in Schedule II to the Companies Act, 2013 except in respect of the following categories of assets, in whose case the life of the assets has been assessed as under based on technical advice, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes and maintenance support, etc.:



Particulars	Useful life as per Management	Useful life as per Schedule II - Companies Act, 2013
Office Equipments	5-10 years	5 years
Plant & Equipments	10 - 25 years	15 years

Based on the internal assessment and technical evaluation carried out by the Company and historical usage of assets; the management believes that the useful lives as given above best represents the period over which management expects to use these assets.

- iii. An item of Property, Plant and Equipment is derecognised on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising on derecognition is recognised in the Statement of Profit and Loss.
- iv. The useful life, residual value and the depreciation method are reviewed at least at each financial year end. If the expectations differ from previous estimates, the changes are accounted for prospectively as a change in accounting estimate.

B. Intangible Assets:

Intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any. Intangible assets are amortised on a straight-line basis over their estimated useful lives. A rebuttable presumption that the useful life of an intangible asset will not exceed ten years from the date when the asset is available for use is considered by the management. The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly.

Gains or losses arising from the retirement or disposal of an intangible asset are determined as the difference between the net disposal proceeds and the carrying amount of the asset and recognised as income or expense in the Statement of Profit and Loss. The estimated useful lives of intangible assets are as follows:

Particulars	Useful life as per Management
Software	5 years or tenure of licenses, whichever is lower.

1.4 Goodwill arising on Amalgamation:

The goodwill is amortised to the Statement of profit and loss on a systematic basis over a period of five years.

1.5 Inventories:


Inventories are valued at the lower of cost and net realisable value after providing for obsolescence and other losses, where considered necessary. Cost includes all charges in bringing the goods to the point of sale, transit insurance, receiving charges and other levies. Work-in-progress and finished goods include appropriate proportion of overheads.

The basis for determining cost for various categories of inventory is as follows:

- i. Raw Materials - on FIFO Basis
- ii. Packing Materials - on FIFO Basis
- iii. Work in Progress - At Absorption Cost
- iv. Finished Goods - At Absorption Cost

1.6 Revenue Recognition:

- i. Revenue from sale of products is recognised when the significant risks and rewards of ownership of goods is transferred to the customer.
- ii. Revenue from sale of services is recognized when services are rendered.



- iii. Export incentives are recognized as income when right to receive credit as per the terms of the scheme is established in respect of the export made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.
- iv. Interest income is recognized on a time proportion basis taking into account the time outstanding and the rate applicable.
- v. Other income is recognized only when its collection is virtually certain and there is no uncertainty over its ultimate collection.

1.7 Investments:

Investments that are readily realisable and are intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. Current investments are carried at cost or fair value, whichever is lower.

All other investments are classified as long-term investments. Long-term investments are carried at cost. However, provision for diminution is made to recognise a decline, other than temporary, in the value of long-term investments, such reduction being determined and made for each investment individually.

1.8 Employee Benefits:

A. Defined Contribution Plan:

The Company contributes to Employees' Provident Fund/Pension Fund, Employees' State Insurance and Labour Welfare Fund. The contributions towards Provident Fund/Pension Fund, Employees' State Insurances and Labour Welfare Fund is made to regulatory authorities. Such benefits are classified as Defined Contribution Schemes as the Company does not carry any further obligations, apart from the contributions made on a monthly basis.

B. Defined Benefit Plan:

Gratuity: The Company provides for gratuity, a defined benefit plan (the "Gratuity Plan") covering eligible employees in accordance with the Payment of Gratuity Act, 1972. The Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/ gains are recognised in the Statement of Profit and Loss in the year in which they arise.

C. Other Long-term Employment Benefit

Accumulated compensated absences, which are expected to be availed or encashed beyond 12 months from the end of the year are treated as other long-term employee benefits. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/ gains are recognised in the Statement of Profit and Loss in the year in which they arise.

Accumulated compensated absences, which are expected to be availed or encashed within 12 months from the end of the year end are treated as short term employee benefits. The obligation towards the same is measured at the expected cost of accumulating compensated absences as the additional amount expected to be paid as a result of the unused entitlement as at the year end.

1.9 Foreign Currency Transactions:


Initial Recognition

On initial recognition, all foreign currency transactions are recorded by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Subsequent Measurement

As at the reporting date, non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. All monetary assets and liabilities in foreign currency are restated at the end of accounting period using the year end rates.

Exchange differences on restatement of all other monetary items are recognised in the Statement of



1.10 Borrowing Cost:

Borrowing costs include interest and amortisation of ancillary borrowing costs incurred. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan. Borrowing costs, allocated to and utilised for qualifying assets, pertaining to the period from commencement of activities relating to construction/development of the qualifying asset up to the date of capitalisation of such asset are added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted, if any.

1.11 Operating leases:

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the Statement of Profit and Loss on a straight-line basis over the period of the lease.

1.12 Impairment:

Assessment is done at each balance sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. An asset or CGU whose carrying value exceeds its recoverable amount is considered impaired and is written down to its recoverable amount. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased. An impairment loss is reversed to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined if no impairment loss had previously been recognised.

1.13 Current and Deferred Tax:

Tax expense for the period, comprising current tax and deferred tax, are included in the determination of the net profit or loss for the period. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the taxation laws prevailing in the respective jurisdictions.

Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences.

Deferred tax assets are recognised and carried forward only to the extent that there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. In situations, where the Company has unabsorbed depreciation or carry forward losses under tax laws, all deferred tax assets are recognised only to the extent that there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits. At each Balance Sheet date, the Company re-assesses unrecognised deferred tax assets, if any.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis. Deferred tax assets and deferred tax liabilities are offset when there is a legally enforceable right to set off assets against liabilities representing current tax and where the deferred tax assets and the deferred tax liabilities relate to taxes on income levied by the same governing taxation laws.



Minimum Alternate Tax (MAT) credit is recognised as an asset only when and to the extent there is convincing evidence that the company will pay normal income tax during the specified period. Such asset is reviewed at each Balance Sheet date and the carrying amount of the MAT credit asset is written down to the extent there is no longer a convincing evidence to the effect that the Company will pay normal income tax during the specified period.

1.14 Provisions and Contingencies:

Provisions: Provisions are recognised when there is a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and there is a reliable estimate of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance sheet date and are not discounted to its present value.

Contingent Liabilities: Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

1.15 Cash and Cash Equivalents:


Cash and cash equivalents include cash on hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

1.16 Earnings per Share:

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earnings considered in ascertaining the Company's earnings per share is the net profit for the period after deducting preference dividends and any attributable tax thereto for the period. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

1.17 Segment Reporting:

In accordance with the requirements of Accounting Standard 17 - 'Segment Reporting', the Company has determined its business segment as 'Manufacturing and sale of pharmaceutical products'. There are no other primary reportable segments.




Amanta Healthcare Limited
Notes to the Financial Statements

2 Share capital	Amount (Rs. in lakhs)	
	As at 31st March, 2021	As at 31st March, 2020
Authorised :		
90,150,000 (Previous year 90,150,000) Equity Shares of Rs. 10 each	9,015.00	9,015.00
Issued, Subscribed and Paid-up :		
26,829,351 (Previous year 26,829,351) Equity Shares of Rs. 10 each	2,682.94	2,682.94
	<u>2,682.94</u>	<u>2,682.94</u>

2.1 There is no movement in number of equity shares and the amount outstanding thereon during current year and previous year.

2.2 **Details of shares held by shareholders holding more than 5% of shares in the Company:**

Particulars	As at 31st March, 2021		As at 31st March, 2020	
	Number of Shares (in lakhs)	%	Number of Shares (in lakhs)	%
Mr. Praful J. Patel	44.72	16.67%	44.72	16.67%
Mr. Jitendra J. Patel	28.41	10.59%	33.76	12.58%
Mr. Bhavesh G. Patel	34.79	12.97%	34.62	12.90%
Mr. Vishal A. Patel	32.84	12.24%	32.84	12.24%
Milcent Appliances Private Limited	31.00	11.55%	31.00	11.55%
Mr. Pravin D. Mehta	28.05	10.45%	28.05	10.45%
Mr. Niranjana Patel	15.03	5.60%	17.26	6.43%
	<u>214.84</u>	<u>80.07%</u>	<u>222.25</u>	<u>82.82%</u>



Amanta Healthcare Limited
Notes to the Financial Statements

Amount (Rs. in lakhs)

2.3 Shares allotted as fully paid up pursuant to scheme of arrangement without payment being received in cash (during 5 years immediately preceding March 31, 2021):
202,982 Equity share of Rs. 10 each has been issued on November 30, 2018 to the shareholders of Marck Remedies Private Limited pursuant to the scheme of amalgamation without payment being received in cash.

2.4 Rights, preferences and restrictions attached to Equity shares:


The Company has one class of equity shares having a par value of Rs. 10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amount, in proportion to their shareholding.

3 Reserves and surplus	As at 31st March, 2021	As at 31st March, 2020
Securities Premium		
Balance as at the beginning of the year	2,098.38	7,950.77
Less: Utilisation of Securities Premium (Note No.3.1)	-	(5,852.39)
Balance as at the end of the year	2,098.38	2,098.38
General Reserve	1.44	1.44
Debenture Redemption Reserve	14.60	14.60
Deficit in the Statement of Profit and Loss		
Balance as at the beginning of the year	(1,887.48)	(5,852.39)
Add : Loss for the year	(2,183.41)	(1,887.48)
Add: Utilisation of Securities Premium (Note No.3.1)	-	5,852.39
Balance as at the end of the year	(4,070.89)	(1,887.48)
Total	(1,956.47)	226.94

3.1 Utilisation of Securities Premium

The Board at its meeting held on January 28, 2019 had approved a Scheme of Capital Reduction under section 66 of the Companies Act, 2013 read with section 52 of the Companies Act 2013 for setting off accumulated losses as per audited Financial statement as at March 31, 2019 (the Scheme) amounting to Rs.5852.39 lakhs against the Securities Premium Account. The Scheme was approved by the shareholders in the Extra ordinary General Meeting dated February 28, 2019, and was sanctioned by the National Company Law Tribunal (NCLT), Ahmedabad Branch vide order dated January 9, 2020. The order of NCLT has been filed with the Registrar of Companies, Gujarat as on February 03, 2020. The effect of such utilisation of share premium has been considered in the financial statements during the year ended March 31, 2020.

4 Long-term borrowings	As at 31st March, 2021		As at 31st March, 2020	
	Non-current	Current	Non-current	Current
Secured				
Non-Convertible Debentures				
990 (Previous year: 990) Redeemable Non-Convertible Debentures of Rs. 82,800 (Previous year 87,129) each	605.88	213.84	819.72	42.86
6334 (Previous year: 6334) Redeemable Non-Convertible Debentures of Rs. 1,00,000 (Previous year 1,00,000) each	5,175.00	1,159.00	6,334.00	-
Term Loans:				
From banks	180.19	316.53	208.09	80.99
From others	8,825.27	2,067.79	10,893.06	178.05
	9,005.46	2,384.32	11,101.15	259.04
Unsecured				
Term Loans:				
From others	666.42	23.07	690.40	19.69
Deposits:				
From members	355.73	87.76	298.74	130.25
Amount disclosed under the head of Other Current Liabilities (Refer note no. 10)	-	(3,867.99)	-	(451.84)
	15,808.49	-	19,244.01	-



Secured Debentures:

- 4.1 The Company has issued following secured redeemable non-convertible debentures:

990 debentures allotted on 7th December, 2017 aggregating to Rs. 819.72 lakhs (Previous Year Rs. 862.58 lakhs), carries interest at the rate of 14% p.a. The cash coupon of 9.5% is payable on quarterly basis. Every repayment of principal amount as per repayment schedule is made along with interest of 4.5% p.a. calculated from the date of disbursement.

6,334 debentures allotted on 7th December, 2017 aggregating to Rs. 6,334.00 lakhs (Previous Year Rs. 6,334.00 lakhs), carries interest at the rate of 14% p.a. The cash coupon of 4.5% is payable on quarterly basis. Every repayment of principal amount as per repayment schedule is made along with interest of 9.5% p.a. calculated from the date of disbursement.

Debentures are to be redeemed as per the agreed redemption schedule by 30th September, 2024 and are secured by (i) first charge on pari-passu basis by equitable mortgage on factory land & building and hypothecation of plant and machineries situated at Kheda unit, both present and future and (ii) second charge on all other current assets like stock, book debts, etc. The loan is further secured by personal guarantee of promoters. Also refer note 44.

Secured Term Loans:

- 4.2 Term loan of Rs. 1,250.28 lakhs (Previous year : Rs. 1,420.91 lakhs) secured by (i) first charge on pari-passu basis by equitable mortgage on factory land & building and hypothecation of plant and machineries situated at Kheda unit, both present and future and (ii) second charge on all other current assets like stock, book debts, etc. The loan is further secured by personal guarantee of promoter. Loan carries interest at the rate of 14% p.a. The cash coupon of 9.5% is payable on quarterly basis. Every repayment of principal amount as per repayment schedule is made along with interest of 4.5% p.a. calculated from the date of disbursement. This loan is repayable as per the agreed yearly installment by 30th September, 2024. Also refer note 44.

- 4.3 Term loan of Rs. 9,642.78 lakhs (Previous year : Rs. 9,642.78 lakhs) secured by (i) first charge on pari-passu basis by equitable mortgage on factory land & building and hypothecation of plant and machineries situated at Kheda unit, both present and future and (ii) second charge on all other current assets like stock, book debts, etc. The loan is further secured by personal guarantee of promoter. Loan carries interest at the rate of 14% p.a. The cash coupon of 4.5% is payable on quarterly basis. Every repayment of principal amount as per repayment schedule is made along with interest of 9.5% p.a. calculated from the date of disbursement. This loan is repayable as per the agreed yearly installment by 30th September, 2024. Also refer note 44.

- 4.4 Term Loans from banks aggregating to Rs. 222.32 lakhs (Previous year : Rs. 296.51 lakhs) is secured by hypothecation of vehicles. These are repayable in 35 to 84 monthly installments. It carries interest rate within range of 9.03% p.a. to 10.14% p.a.

- 4.5 Term loan from bank amounting to Rs. 274.40 lakhs (Previous year: Nil). This is repayable in 18 monthly installments starting 6 months from the date of first disbursement. It carries interest rate of 7.40% p.a. It is secured by hypothecation of (i) entire stocks of raw materials, work-in-process, finished goods, consumables stores and spares and such other movables including trade receivables, both present and future and (ii) first charge on pari-passu basis on all fixed assets of the Kheda unit. The loan is further secured by personal guarantee of promoters.


Unsecured Terms Loans:

- 4.6 The Company has availed unsecured loan amounting to Rs. 689.49 lakhs (Previous year : Rs. 710.09 lakhs). This is repayable in 180 monthly installments. It carries interest rate of HFR plus 0.35%. One of the Director of the Company has provided his personal residential property as security to obtain the loan for the Company and director himself. The director has accepted his personal liability towards his share in the loan by entering into a separate arrangement with the Company. The share of monthly installments including the interest thereon are regularly paid by the director to the Company before it's due date.

Unsecured Deposits from members:


- 4.7 Deposits are repayable in 6 to 36 months from the date of deposit. It carries interest from 0% p.a. to 12% p.a.

5 Deferred tax liabilities (Net)	As at 31st March, 2021	As at 31st March, 2020
Deferred Tax Liability		
Depreciation	3,990.77	3,919.00
Unamortised ancillary borrowing cost	84.57	129.31
	<u>4,075.34</u>	<u>4,048.31</u>
Deferred Tax Assets		
Provision for bonus	8.43	8.52
Provision for gratuity and leave encashment	134.07	120.40
Provision for doubtful debts	53.05	70.58
	<u>195.55</u>	<u>199.50</u>
	<u>3,879.79</u>	<u>3,848.81</u>



Amanta Healthcare Limited
Notes to the Financial Statements

	Amount (Rs. in lakhs)	
	As at	As at
	31st March, 2021	31st March, 2020
6 Other long-term liabilities		
Interest accrued but not due on borrowings	6,050.85	5,026.78
	<u>6,050.85</u>	<u>5,026.78</u>
7 Long-term provisions		
Provision for Employee Benefits (Refer note no. 26):		
- Provision for Gratuity	321.39	279.89
- Provision for Leave Encashment	132.93	127.75
	<u>454.32</u>	<u>407.64</u>
8 Short-term borrowings		
As at	As at	
31st March, 2021	31st March, 2020	
Secured		
Cash Credit		
From bank (Refer note 8.1 below)	3,703.02	3,364.28
Deposits:		
From members (Refer note 8.2 below)	85.35	56.82
	<u>3,788.37</u>	<u>3,421.10</u>
8.1 Cash credit facility from bank is secured by hypothecation of (i) entire stocks of raw materials, work-in-process, finished goods, consumables stores and spares and such other movables including trade receivables, both present and future and (ii) first charge on pari-passu basis on all fixed assets of the Kheda unit. The facility is further secured by personal guarantee of two directors. It carries interest of MCLR plus 2.00%.		
8.2 Deposits carries interest from 0% to 12% p.a.		
9 Trade Payables		
As at	As at	
31st March, 2021	31st March, 2020	
(i) Total outstanding dues of micro and small enterprises (Refer note no. 35)	466.46	138.76
(ii) Total outstanding dues of creditors other than micro and small enterprises	2,063.48	1,588.03
	<u>2,529.94</u>	<u>1,726.79</u>
10 Other current liabilities		
As at	As at	
31st March, 2021	31st March, 2020	
Current maturities of long-term borrowings (Refer note no. 4)	3,867.99	451.84
Interest accrued but not due on borrowings	960.40	230.27
Creditors for capital goods	119.13	427.87
Advances from customers	337.40	294.92
Statutory dues	142.07	260.20
Employee benefits payable	202.78	213.58
Interest payable to micro enterprises and small enterprises	8.56	4.17
Others*	5.71	14.17
	<u>5,644.04</u>	<u>1,897.02</u>
* Includes remuneration payable to directors Rs. 5.71 lakhs (Previous year Rs. 3.46 lakhs) (Refer note 40)		
11 Short-term provisions		
As at	As at	
31st March, 2021	31st March, 2020	
Provision for Employee Benefits (Refer note no. 26):		
- Provision for Leave Encashment	6.08	4.50
	<u>6.08</u>	<u>4.50</u>
Other provisions:		
Provision for Income Tax [(Net of Advance Tax Rs.9.72 lakhs (Previous year Rs. 373.25 lakhs)]	322.68	334.77
	<u>328.76</u>	<u>339.27</u>




12(a) Property, plant and equipment (Tangible Assets)

Amount (Rs. in lakhs)

Particulars	Gross Block			Depreciation			Net Block	
	As at 1st April, 2020	Addition	Disposal	As at 31st March, 2021	Upto 1st April, 2020	For the Year	Disposals	Upto 31st March, 2021
Freehold Land	81.74	-	-	81.74	-	-	-	-
Buildings	5,246.16	238.48	-	5,484.64	1,802.14	165.81	-	1,967.95
Plant and Equipments	30,048.06	1,350.40	1,207.93	30,190.53	11,007.56	1,157.25	1,057.29	11,107.52
Electric Installations	2,347.88	52.73	-	2,400.61	1,247.16	189.90	-	1,437.06
Furniture and Fixtures	398.41	-	-	398.41	312.48	16.28	-	328.76
Office Equipments	371.59	7.44	-	379.03	305.83	21.69	-	327.52
Vehicles	526.46	3.58	78.48	451.56	146.68	58.51	61.49	143.70
Total	39,020.30	1,652.63	1,286.41	39,386.52	14,821.85	1,609.44	1,118.78	15,312.51

Particulars	Gross Block			Depreciation			Net Block	
	As at 1st April, 2019	Addition	Disposal	As at 31st March, 2020	Upto 1st April, 2019	For the Year	Disposals	Upto 31st March, 2020
Freehold Land	81.74	-	-	81.74	-	-	-	-
Buildings	5,229.47	16.69	-	5,246.16	1,638.91	163.23	-	1,802.14
Plant and Equipments	29,190.38	857.68	-	30,048.06	9,883.41	1,124.15	-	11,007.56
Electric Installations	2,101.85	246.03	-	2,347.88	1,078.06	169.10	-	1,247.16
Furniture and Fixtures	398.41	-	-	398.41	294.99	17.49	-	312.48
Office Equipments	361.58	10.01	-	371.59	282.60	23.23	-	305.83
Vehicles	416.95	209.42	99.91	526.46	175.33	59.29	87.94	146.68
Total	37,780.38	1,339.83	99.91	39,020.30	13,353.30	1,556.49	87.94	14,821.85



Amanta Healthcare Limited
Notes to the Financial Statements

12(b) Intangible Assets


Particulars	Gross Block			Amortisation			Net Block			
	As at 1st April, 2020	Addition	Disposal	As at 31st March, 2021	Upto 1st April, 2020	For the Year	Disposals	Upto 31st March, 2021	As at 31st March, 2021	As at 31st March, 2020
Computer Software	98.98	8.00	-	106.98	76.13	8.38	-	84.51	22.47	22.85
Goodwill	422.76	-	-	422.76	253.65	84.55	-	338.20	84.56	169.11
Total	521.74	8.00	-	529.74	329.78	92.93	-	422.71	107.03	191.96

Particulars	Gross Block			Amortisation				Net Block		
	As at 1st April, 2019	Addition	Disposal	As at 31st March, 2020	Upto 1st April, 2019	For the Year	Disposals	Upto 31st March, 2020	As at 31st March, 2020	As at 31st March, 2019
Computer Software	72.19	26.79	-	98.98	67.88	8.25	-	76.13	22.85	4.31
Goodwill	422.76	-	-	422.76	169.10	84.55	-	253.65	169.11	253.66
total	494.95	26.79	-	521.74	236.98	92.80	-	329.78	191.96	257.97



Amanta Healthcare Limited
Notes to the Financial Statements

	Amount (Rs. in lakhs)	
	As at	As at
	31st March, 2021	31st March, 2020
13 Non-current investments		
Unquoted Long-term Investments (Valued at cost)		
Investment in Mutual Funds		
Nil (Previous Year: 100,000) Units of SBI Dual Advantage Fund Series XXIV Regular Growth Plan of NAV of Rs. 10.45 each	-	10.00
Investment in Equity shares		
50 Equity shares of Natpur Co-op Bank Limited of Rs. 10 each, fully paid-up	-	-
1,950,000 Equity shares of SKAPS Limited of Rs 10 each, fully paid-up	-	-
	<u>-</u>	<u>10.00</u>
14 Long-term loans and advances		
	As at	As at
	31st March, 2021	31st March, 2020
Unsecured, considered Good:		
Capital Advances	519.71	1,140.54
Security Deposits	188.65	168.72
Advance Income Tax [Net of Provision Rs. Nil (Previous year Rs. 895.17 lakhs)]	15.23	581.90
MAT Credit Entitlement	996.47	1,668.66
Loans to Employees	16.73	19.38
	<u>1,736.79</u>	<u>3,579.20</u>
15 Other non-current assets		
	As at	As at
	31st March, 2021	31st March, 2020
Long term deposits with Bank with maturity period more than 12 months*	51.63	10.24
Unamortised ancillary borrowing cost	163.70	290.42
	<u>215.33</u>	<u>300.66</u>
*includes Margin money deposit Rs. Nil (Previous year Rs. 10.24 lakhs) with banks for opening Letter of Credit and Bank Guarantee.		
16 Current Investment		
	As at	As at
	31st March, 2021	31st March, 2020
Investment in Mutual Fund (Unquoted)	150.00	-
603,954 Units of SBI Dual Advantage Fund Series XXIV Regular Growth Plan		
	<u>150.00</u>	<u>-</u>
17 Inventories		
(At lower of cost and net realisable value)	As at	As at
	31st March, 2021	31st March, 2020
Raw materials*	1,088.15	846.20
Packing materials	467.53	350.80
Work-in-process	875.82	560.70
Finished goods	2,873.51	2,088.95
Finished goods in transit	170.62	63.97
Stock-in-trade	248.44	22.88
	<u>5,724.07</u>	<u>3,933.50</u>
*Includes raw materials in bonded warehouse amounting to Rs 775.20 lakhs (Previous year Rs. 415.06 lakhs)		
18 Trade receivables		
	As at	As at
	31st March, 2021	31st March, 2020
Unsecured:		
Outstanding for the period exceeding six months from the date they were due for payment		
- Considered good	1,344.11	1,479.52
- Considered doubtful	182.17	242.39
Less: Provision for doubtful debts	(182.17)	(242.39)
	<u>1,344.11</u>	<u>1,479.52</u>
Others, considered good	3,803.75	3,728.46
	<u>5,147.86</u>	<u>5,207.98</u>




Amanta Healthcare Limited
Notes to the Financial Statements

19 Cash and bank balances	Amount (Rs. in lakhs)	
	As at 31st March, 2021	As at 31st March, 2020
Cash and cash equivalents		
- Cash on hand	16.82	23.03
- Balances with banks		
in Current Accounts	4.90	83.42
in Deposit Accounts		
- Fixed Deposit having original maturity of less than 3 months	66.58	-
	88.30	106.45
Other bank balances		
Deposits with maturity more than 3 months but less than 12 months*	799.00	515.74
	<u>887.30</u>	<u>622.19</u>


*includes Margin money deposit Rs. 637.11 lakhs (Previous year Rs. 444.13 lakhs) with banks for opening Letter of Credit and Bank Guarantee.

20 Short-term loans and advances	Amount (Rs. in lakhs)	
	As at 31st March, 2021	As at 31st March, 2020
Unsecured, Considered Good		
Balances with Government Authorities	370.63	211.14
Loans to Employees	13.67	18.22
Advances to Employees	27.21	38.30
Prepaid Expenses	73.89	47.60
Advance to Trade creditors	25.11	104.70
MAT Credit Entitlement	332.40	-
Others	2.45	3.05
	<u>845.36</u>	<u>423.01</u>
21 Other current assets		
	As at 31st March, 2021	As at 31st March, 2020
Export Benefits Receivables	179.79	188.14
Interest accrued on deposits with banks	16.77	12.58
Unamortised ancillary borrowing cost	126.72	153.63
	<u>323.28</u>	<u>354.35</u>



Amanta Healthcare Limited
Notes to the Financial Statements

		Amount (Rs. in lakhs)			
22	Revenue from operations	2020-21	2019-20		
	Sale of Products	16,881.98	18,233.15		
	Sale of Services	11.31	4.68		
		16,893.29	18,237.83		
	Other Operating Revenue:				
	Scrap sales	28.46	42.34		
	Export Incentives	207.71	156.62		
		17,129.46	18,436.79		
	Note - Sale of products comprises sale of finished goods classified as under:				
	Large Volume Parenterals	11,735.37	13,411.07		
	Small Volume Parenterals	5,037.89	4,680.15		
	Others	108.72	141.93		
		16,881.98	18,233.15		
23	Other income	2020-21	2019-20		
	Interest Income (Refer note below)	65.04	40.20		
	Net gain on foreign currency transactions & translation	28.22	155.97		
	Insurance claims received	6.29	8.91		
	Liabilities written back to the extent no longer required	6.73	8.06		
	Miscellaneous income	0.04	0.13		
		106.32	213.27		
	Note - Interest income comprises of:				
	- Interest on deposits with banks	35.50	34.30		
	- Others	29.54	5.90		
		65.04	40.20		
24	Cost of materials consumed	2020-21	2019-20		
	Raw Material	3,453.54	3,965.65		
	Packing Material	2,441.11	2,584.89		
		5,894.65	6,550.54		
	(a) Details of material consumed:				
	Plastic	2,703.52	3,143.40		
	Dextrose	245.60	319.90		
	Others	2,945.53	3,087.24		
	Total	5,894.65	6,550.54		
	(b) Value of imported and indigenous materials consumed:				
	Particulars	2020-21	2019-20		
		Rs. In lakhs	%	Rs. In lakhs	%
	Raw Materials (including packing material)				
	Imported	2,727.28	46.27%	3,181.25	48.56%
	Indigenous	3,167.37	53.73%	3,369.29	51.44%
		5,894.65	100%	6,550.54	100%



Amanta Healthcare Limited
Notes to the Financial Statements

		Amount (Rs. in lakhs)	
25	Changes in inventories of finished goods, work-in-process and stock-in-trade	2020-21	2019-20
	Opening Balance		
	Finished goods	2,152.92	2,054.16
	Work-in-process	560.70	258.95
	Stock-in-trade	22.88	33.46
		<u>2,736.50</u>	<u>2,346.57</u>
	Less: Closing Balance		
	Finished goods	3,044.13	2,152.92
	Work-in-process	875.82	560.70
	Stock-in-trade	248.44	22.88
		<u>4,168.39</u>	<u>2,736.50</u>
	Net increase in inventories	<u>(1,431.89)</u>	<u>(389.93)</u>

26	Employee benefits expense	2020-21	2019-20
	Salaries and Wages	3,228.09	3,105.57
	Contribution to Provident and Other Funds (Refer note (a) below)	137.10	127.43
	Gratuity (Refer note (b) below)	46.37	63.17
	Staff Welfare Expenses	31.44	33.23
		<u>3,443.00</u>	<u>3,329.40</u>

(a) Defined Contribution Plans

Amount recognised in the Statement of Profit and loss

(i) Contribution to Provident fund	69.08	67.38
(ii) Contribution to Pension fund	66.65	58.40
(iii) Contribution to ESI	0.86	1.20
(iv) Contribution to Labour welfare fund	0.51	0.45
Total	<u>137.10</u>	<u>127.43</u>

(b) Defined Benefit Plans

The Company has a funded defined benefit gratuity plan. Every employee is entitled to a benefit equivalent to fifteen days salary last drawn for each completed year of service. The same is payable at the time of separation from the Company or retirement, whichever is earlier. The fund is managed by Life Insurance Corporation of India. Following are the further particulars with respect to gratuity for the year ended March 31, 2021.

Gratuity:

Present value of the Defined Benefit obligation:


Particulars	2020-21	2019-20
Obligation at the beginning of the year	298.46	246.00
Current service cost	31.85	28.99
Interest cost	19.40	17.96
Actuarial (gain)/loss	(3.60)	17.48
Benefits paid	(4.89)	(11.97)
Obligation at the end of the year	<u>341.22</u>	<u>298.46</u>

Fair Value of Plan Assets

Particulars	2020-21	2019-20
Fair value of plan assets at the beginning of the year	18.55	17.29
Expected return on plan assets	1.20	1.26
Actuarial gain	0.08	-
Contributions by employer	4.89	11.97
Benefits paid	(4.89)	(11.97)
Fair value of plan assets at the end of the year	<u>19.83</u>	<u>18.55</u>

Expense recognised in Statement of Profit & Loss

Particulars	2020-21	2019-20
Current service cost	31.85	28.99
Interest cost	19.40	17.96
Expected return on plan assets	(1.20)	(1.26)
Net actuarial (gains)/ losses	(3.68)	17.48
Total Expenses	<u>46.37</u>	<u>63.17</u>



Amanta Healthcare Limited
Notes to the Financial Statements

Amount (Rs. in lakhs)

Assets & Liabilities recognised in the Balance Sheet

Particulars	2020-21	2019-20
Present value of Defined Benefit obligations	(341.22)	(298.46)
Fair Value of plan assets as at the end of the year	19.83	18.55
Amount recognised as liability	<u>(321.39)</u>	<u>(279.91)</u>
Long-term provision (Refer note no. 7)	321.39	279.91
	<u>321.39</u>	<u>279.91</u>

Percentage Break-down of Total Plan Assets

Particulars	2020-21	2019-20
Insurer Managed Funds (Traditional, Non Market Linked)	100%	100%

Actuarial assumptions

Particulars	2020-21	2019-20
Discount Rate	6.60%	6.50%
Expected rate of return on plan assets	6.50%	7.30%
Salary growth rate	5.50%	5.50%

Future mortality rates are obtained from relevant table of Indian Assured Lives Mortality (2012-14) Ultimate as at March 31, 2021 and March 31, 2020.

Withdrawal rates:

- 2020-21	Upto 35 years - 5% p.a and beyond 35 years - 2% p.a
- 2019-20	Upto 35 years - 5% p.a and beyond 35 years - 2% p.a

Actuarial valuation method used is Projected Unit Credit Method

Amounts recognised in Current year and previous four years

	2020-21	2019-20	2018-19	2017-18	2016-17
Defined Benefit Obligation at end of the year	(341.22)	(298.46)	(246.00)	(220.18)	(184.53)
Fair value of plan assets at end of the year	19.83	18.55	17.29	16.04	14.90
Deficit	(321.39)	(279.91)	(228.71)	(204.14)	(169.63)
Experience adjustment in plan liabilities	0.99	1.06	(9.34)	0.51	(7.41)
Experience adjustment in plan assets	(0.07)	(0.05)	0.15	0.01	0.04

Expected gratuity contribution for the next year is Rs. 10 lakhs (Previous year : Rs. 10 lakhs)


(c) Other Long-term Employment Benefit

This includes Compensated absences. The amount charged to the Statement of Profit and Loss for the year is Rs. 40.90 lakhs (Previous year: Rs. 72.67 lakhs). The actuarial liability for compensated absences for the year ended March 31, 2021 :

Particulars	2020-21	2019-20
Long-term provision (Refer note no. 7)	132.93	127.75
Short-term provision (Refer note no. 11)	6.08	4.50
	<u>139.01</u>	<u>132.25</u>

27 Finance costs	2020-21	2019-20
Interest Expense	3,809.32	3,535.71
Other Borrowing Costs*	203.86	277.16
	<u>4,013.18</u>	<u>3,812.87</u>

*includes amortisation of ancillary borrowing cost amounting to Rs. 153.63 lakhs (Previous year Rs. 158.67)




Amanta Healthcare Limited
Notes to the Financial Statements

	Amount (Rs. in lakhs)	
	2020-21	2019-20
28 Other expenses		
Consumption of Stores and Spare parts (Refer note below)	265.44	319.86
Power and Fuel	1,424.14	1,835.96
Laboratory Goods and Testing Expenses	134.65	109.33
Repairs to Buildings	23.79	21.84
Repairs to Machinery	73.89	51.27
Repairs to Others	45.36	33.91
Communication Expenses	20.76	21.15
Legal and Professional Expenses	148.14	102.73
Printing and Stationery Expenses	47.72	31.55
Rent [Prior period expense- Rs. 14.99 lakhs (Previous year: Nil)]	204.16	158.20
Rates and Taxes	103.71	132.23
Insurance	82.92	49.47
Security Service Charges	47.72	43.89
Travelling and Conveyance Expenses	182.00	243.55
Payment to Auditors		
As auditors:		
Statutory Audit	11.00	11.00
Certification	1.00	1.00
In respect of other audit services:		
Tax Audit	2.50	2.50
Vehicle Running and Maintenance	67.98	84.26
Provision for doubtful trade receivables		
Bad Debts	136.21	-
Less: Withdrawal from provision for doubtful debts	(136.21)	-
Provision for doubtful debts	75.99	29.24
	75.99	29.24
Loss on sale of assets (net)	15.34	9.03
Corporate Social Responsibility (Refer note 39)	78.57	94.73
Freight and Forwarding Expenses	1,389.58	1,365.55
Selling and Distribution Expenses	346.11	161.11
General Expenses	107.88	74.47
	4,900.35	4,987.83

Note: Value of imported and indigenous materials consumed

Particulars	2020-21		2019-20	
	Rs. in lakhs	%	Rs. in lakhs	%
Stores and Spares				
Imported	21.06	7.93%	16.90	5.28%
Indigenous	244.38	92.07%	302.96	94.72%
	265.44	100%	319.86	100%

29 CIF Value of Imports	2020-21	2019-20
Raw Materials	2,629.96	2,439.12
Stores and Spares	21.06	13.09
	2,651.02	2,452.21
30 Expenditure in foreign currency	2020-21	2019-20
Foreign Travelling Expenses	-	5.67
Commission	141.34	-
Other expenses	50.37	53.99
	191.71	59.66
31 Earnings in foreign currency	2020-21	2019-20
FOB Value of Exports	5,927.58	4,589.43
	5,927.58	4,589.43



Amanta Healthcare Limited
Notes to the Financial Statements

Notes to the Financial Statements

		Amount (Rs. in lakhs)			
32	Unhedged foreign currency exposure	2020-21		2019-20	
		Foreign Currency (In lakhs)	Amount (Rs. in lakhs)	Foreign Currency (In lakhs)	Amount (Rs. in lakhs)
	Trade receivables				
	AUD*	0.92	51.01	0.92	42.02
	GBP	0.89	89.55	2.14	197.67
	USD	9.97	730.27	7.71	576.08
			<u>870.83</u>		<u>815.77</u>
	*Amount of AUD 91,569.35 (Previous year : AUD 91,569.35)				
	Trade payables				
	USD	0.44	32.43	-	-
			<u>32.43</u>		<u>-</u>
	Cash/bank balance				
	USD	0.04	2.71	0.04	2.77
	GBP@	0.00	0.41	0.00	0.37
	EUR#	0.00	0.24	0.00	0.23
	Others**	0.01	0.87	0.01	0.86
			<u>4.23</u>		<u>4.23</u>

@ Amount of GBP 405 (Previous year : GBP 405)

Amount of EUR 274.05 (Previous year : EUR 274.05)

**includes multiple foreign currencies on hand


33	Capital commitments
	Estimated amount of contracts remaining to be executed and not provided for (net of advances): Rs. 696.56 lakhs (Previous year: Rs. 277.16 lakhs)

34	Other commitments
	The Company has imported certain goods at concessional rate of custom duty under "Advance License Scheme" of the Central Government. The Company has undertaken an incremental export obligation to the extent of US \$ 0.53 lakhs (Previous year US \$ 1.7 lakhs) equivalent to Rs. 39.73 lakhs (Previous year Rs. 124.65 lakhs) to be fulfilled during a specified period as applicable from the date of imports. The unprovided liability towards custom duty payable on unfulfilled export obligations is Rs. 4.22 lakhs (Previous year Rs. 7.42 lakhs).

35	The Company has certain dues payable to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ("MSMED Act"). The disclosures pursuant to the said MSMED Act are as follows: (Refer note 9)
----	---

	2020-21	2019-20
Principal amount outstanding to suppliers registered under the MSMED Act and remaining unpaid as at year end	466.46	138.76
Interest due on above principal amount payable to suppliers registered under the MSMED Act and remaining unpaid as at year end	0.59	4.17
Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	695.23	-
Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	4.17	-
Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
Interest due and payable towards suppliers registered under MSMED Act, for payments already made	7.97	-
Interest accrued and remaining unpaid at the end of each accounting year	8.56	-
Further interest remaining due and payable for earlier years	-	-

Note: The above information regarding dues payable to Micro and Small enterprises is compiled by management to the extent the information is available with the Company regarding the status of suppliers as Micro and Small enterprises.



Amanta Healthcare Limited
Notes to the Financial Statements

Amount (Rs. in lakhs)

36 Contingent liabilities		
Contingent liabilities not provided for in respect of:		
Particulars	2020-21	2019-20
Claim against company not acknowledged as debt:		
Sales tax liability for matters pending in appeals	-	0.04
Service tax liability for matters pending in appeals	7.46	7.46
Liability towards arbitration order for matter pending in High court	-	24.17

37 Segment reporting

a) Primary segment:

In accordance with the requirements of Accounting Standard 17 - "Segment Reporting" the Company has determined its business segment as Manufacturing and sale of pharmaceutical products. Since 100% of the Company's business is from Manufacturing and sale of pharmaceutical products, there are no other reportable segments. Thus the segment revenue, segment result, total carrying amount of segment assets, total carrying amount of segment liabilities, total cost incurred to acquired segments assets, the total amount of charge for depreciation and amortisation during the year are all as reflected in the financial statements for the year ended 31st March, 2021 and as on that date.

b) Secondary segments (By geography):

Particulars	For the year ended 31st March, 2021			For the year ended 31st March, 2020		
	India	Outside India	Total	India	Outside India	Total
	Rs. (in lakhs)	Rs. (in lakhs)	Rs. (in lakhs)	Rs. (in lakhs)	Rs. (in lakhs)	Rs. (in lakhs)
Revenue From Customers	10,960.02	5,933.27	16,893.29	13,155.85	5,081.98	18,237.83
Carrying Amount of Segment Assets	38,340.20	870.83	39,211.03	37,951.26	815.77	38,767.03
Addition to Property Plant and equipment during the year	1,039.80	-	1,039.80	1,099.70	-	1,099.70

38 Operating leases

The Company has taken office premises and godowns on operating lease for which lease payments recognised in the Statement of profit and loss for the year is Rs. 204.16 lakhs (Previous year Rs. 158.20 lakhs).


	2020-21	2019-20
The total future minimum lease payments under non-cancellable lease are as below:		
Not later than 1 Year	39.23	56.62
Later than 1 Year and not later than 5 Years	17.89	100.20
	<u>57.12</u>	<u>156.82</u>

39 Corporate social responsibility expenditure

a As per section 135 of the Companies Act, 2013, the Company is not required to spend on CSR during the year ended March 31, 2021. Amount spent on CSR during the year represents amounts required to be spend as per Section 135 of the Companies Act, 2013 in respect of earlier years.

b Amount spent during the year on :

Particulars	In cash	Yet to be paid in cash	Total
(i) Construction/acquisition of any assets	-	-	-
(ii) On purposes other than (i) above	78.57	-	78.57



Amanta Healthcare Limited
Notes to the Financial Statements

41 Earnings per share	Amount (Rs. in lakhs)	
	2020-21	2019-20
Weighted average no. of equity shares at the end of the year	Nos. (lakhs) 268.29	268.29
Loss for the year	Rs. (lakhs) (2,183.41)	(1,887.48)
Basic and Diluted loss per share	Rs. (8.14)	(7.04)
Nominal value of equity share	Rs. 10	10

42 The Company has valued the impact of the recent Supreme Court Judgment in case of "Vivekananda Vidyamandir And Others Vs The Regional Provident Fund Commissioner (II) West Bengal" and the related circular (Circular No. C-1/1(33)2019/ Vivekananda Vidya Mandir/284) dated March 20, 2019 issued by the Employees' Provident Fund Organisation in relation to nonexclusion of certain allowances from the definition of "basic wages" of the relevant employees for the purposes of determining contribution to provident fund under the Employees' Provident Funds & Miscellaneous Provisions Act, 1952. The amount of additional liability, if any, is recoverable from the employees as per the employment contracts. Accordingly, in the assessment of the management, the aforesaid matter is not likely to have a material impact on the financial statement of the Company.

43 Impact due to Covid-19 pandemic

Since the Company is in the business of manufacturing essential goods (Pharmaceutical products), the Company was in operations in accordance with the various directives of the Government. the Company's operations have not been affected due to the Covid-19 pandemic. The COVID-19 crisis has caused significant disturbance and slowdown of economic activity. The Company's Management has done an assessment of the situation, including the liquidity position and the recoverability and carrying value of all its assets and liabilities as at March 31, 2021, and concluded that there are no material adjustments required in the financial statements as of March 31, 2021. However, the impact assessment of COVID-19 is a continuing process given the uncertainty associated with its nature and duration. The Company will continue to monitor any material changes as the situation evolves.

44 Subsequent to the year ended March 31, 2021, the Company has entered into an arrangement with a lender for refinancing of certain secured non-convertible debentures and term loans aggregating to Rs. 18,046.78 lakhs as at March 31, 2021 and repayment of accrued interest thereon aggregating to Rs. 7,011.25 as at March 31, 2021.

45 The previous year figures have been regrouped/re-classified to conform to the current year's classification.

In terms of our report of even date.

For Price Waterhouse Chartered Accountants LLP
Chartered Accountants
Firm Registration No.: 012754N/N500016

Viren Shah

Viren Shah
Partner
Membership No: 046521

Place: Ahmedabad
Date: August 31, 2021

For and on behalf of Board of Directors

S. M. Shah
Surendra M. Shah
Director
DIN: 00016678

Shailesh M. Shah
Chief Finance Officer

Bhavesh G. Patel
Bhavesh G. Patel
Managing Director
DIN: 00085505

Shivani Thaker
Company Secretary

Place: Ahmedabad
Date: August 28, 2021

